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Enhancer of zeste homologue 2 (EZH2) is the catalytic subunit of 
Polycomb repressive complex 2 (PRC2) and catalyzes the trimethylation of 
histone H3 on lysine 27 (H3K27Me3), to repress gene transcription. Many types 
of cancer stem and progenitor cells; including breast have demonstrated EZH2 to 
be fundamental in the biology and promoting the expansion of their cellular 
populations. How EZH2 regulates each of these respective CSC or tumor 
initiating cells (TICs) populations has been studied in a laboratory setting, but the 
signaling transduction mechanisms that regulate EZH2 in these CSC populations 
is yet to be elucidated. Phosphorylation of EZH2 by cyclin dependent kinases 
(CDK) has has been reported to control EZH2 epigenetic function and 
consequently in controlling cancer cell proliferation, invasion, and stem cell 
differentiation. Our group has established that EZH2 and cyclin E, the enzymatic 
activator of CDK2, co-expresses with clinical significance in patient biopsies of 
triple-negative breast cancer (TNBC) compared to normal breast cancer. 
Thereafter we demonstrated CDK2 phosphorylates EZH2 endogenously on 
residue T416 in breast cancer cell lines in a cell cycle-dependent manner. EZH2-
T416 phosphorylation (pT416) enhances the ability of EZH2 to increase cell 
migration/invasion, mammosphere formation, and in vivo tumor growth. Tumor 
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growth and mammosphere formation are both mitigated with administration of 
CDK2 clinical trial inhibitor SNS032. Most importantly EZH2-T416 
phosphorylation (pT416) correlates with poor patient survival specifically in TNBC 
patient biopsies paralleling the EZH2/Cyclin E IHC staining previously observed 
in TNBC biopsy cohorts. Therefore, we postulate pT416 to be a biomarker for 
aggressive forms of breast cancer, including TNBC and propose CDK2 inhibitor 
based therapy as a potential regimen for reducing the size of the breast cancer 
stem cell population and coordinately tumor size. 
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CHAPTER 1. INTRODUCTION 
1.1 Breast cancer target therapy 
The most common cancer in the United States is breast cancer and 
despite advances in in the clinical care an estimated 200,000 new cases with 
40,000 deaths is estimated annually making it a problem of emphasis in the 
United States Public Health Care System1,2. Cytotoxic chemotherapies serve as 
adjuvant treatment regimens based on their inhibition of cell divisions, but the 
non-specific nature of these therapies produce marginal and often times adverse 
effects to patients3. As is the case with many solid tumors the current strategy of 
drug development has been directed to develop drugs for the inhibition of specific 
tumor biomolecules needed for the growth and upkeep of the tumor biology4-7. 
Targeting molecules that are unique to the function of only the tumor will kill the 
tumor cells and not the non-cancer cells surrounding the tumor mass via a 
“smart-knife”-small molecule-pharmacological approach with the hope of 
improving therapy specificity and efficacy.  
1.1.1 Subtypes of breast cancers based on gene expression profiling 
Breast cancer is a heterogeneous disease8-11. Currently, clinical-
pathologic criteria are used to guide therapy decisions. However, anatomic 
pathology does not accurately define tumor biology, as tumors of the same grade 
and stage often behave very differently. As a result, a significant proportion of 
patients who received standard treatment will relapse because of ineffective 
therapy12. The use of transcriptional profiling has shown that breast cancer is a 
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conglomerate of at least five distinct molecular subtypes: luminal A, luminal B, 
Her2 positive, basal-like and normal breast-like13. Notably this molecular 
classification was done in a relatively small number of breast cancer tissues, but 
later validation of the five subtypes has been supported by analysis of over 1000 
breast cancer tissues. From the 1000 breast cancer patient cohort straight 
forward and distinct stratification criteria were put forward14-16. For a brief 
example of the microarray established criteria, both luminal A and luminal B 
breast cancers are considered widely to be estrogen receptor positive. The Her2 
positive subtype represents a group of breast cancers with overexpression or 
gene amplification, determined by FISH, of the Her2 receptor. The basal-like 
group or basal-like breast cancer (BLBC) demonstrates no ER, PgR or Her2 
expression, thus is also termed triple-negative breast cancer (TNBC) in clinic, 
which is how nomenclature, ER-, PgR- and Her2-, was devised. The normal 
breast-like at times is not thought to be a breast cancer subtype and instead is 
thought to be contamination of normal breast tissue from the array analysis14-16. 
Overall the 4 remaining subtypes that are skeptical of being microarray artifacts 
are clearly associated with different clinical features listed in more detail in Table 
1.  
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Table 1. Breast cancer subtype classification 
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Of the classified groups, the BLBC or TNBC tumors are the most difficult tumors 
to treat. TNBC tumors demonstrate higher rates of therapy resistance, 
reoccurrence, metastasis, and therefore worse overall and relapse-free survival 
compared to the other subtypes.  
1.1.2 Therapeutic implications of breast cancer subtypes 
The molecular sub-classification of breast cancer into the 4 clinically 
relevant subtypes, excluding the normal breast-like as an array artifact, provided 
breast cancer oncologist with a biomarker based strategy for diagnosing and 
administering therapy14-16. Yes, the understanding that luminal breast cancers 
expressing the estrogen receptor are prime candidates for tamoxifen, 
aramostase, or anti-endocrine therapy or that Her2 positive breast cancers are 
apt candidates for Herceptin or lapatinib treatment was a clinically useful 
determinant in making decisions for the correct treatment for patients17-19, but 
further reclassification is required. The decisions to use the above mentioned 
treatments and chemotherapies has been widely estimated based on tumor size, 
tumor grade, lymph node status, histopathological features, and the  IHC staining 
for ER, PgR and Her2 and hasserved useful, but also has led to inadequacies 
and even overtreatment. The elucidation of new biomarkers for prediction of 
better therapy response is needed. Predictive diagnoses followed with 
corresponding and matching therapy treatment will reduce treatment side effects 
and maximize therapy efficacy with the avoidment of overtreatment20,21. A full 
gene expression profile or gene mutation status of patients and their known 
therapy responses would help to identify new therapeutic targets based on the 
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response rate according to specific treatment22, thus going beyond the concept of 
overexpression breeding clinical relevance of the thus instead providing clinicians 
with a therapeutic marker capable of predicting patient response to drug therapy. 
Such a strategy would prove exceptionally useful in in ER- or basal-like breast 
cancer tumors in order to provide a benefit for these patients for the clinical 
development of treatment planning, therapeutic response, and prognosis 
prediction23. 
1.1.3 Basal-like breast cancer classification and available treatments  
Basal-like breast cancer comprises of 15-20% of all diagnosed breast 
cancer24. At first these type of breast tumors were characterized based on their 
similarities with cells of the breast basal myoepithelial cell layer due to their cell 
similarities in composition with high molecular weight cytokeratins25. Further 
characterization required in order for these breast tumors to be determined 
basal-like breast cancer that additional cell markers, now termed basal-markers, 
such as c-KIT, alpha smooth muscle actin (SMA), EGFR, cytokeratins (CK) 5, 
CK6, CK 14, CK17, P-cadherin and p6325-29. Current classification schemes that 
designate breast cancer as basal-like as well as determine the classification into 
the three other possible breast cancer subtypes include the 70-gene assay 
(MammaPrint, Agendia, Netherlands), the 21-gene assay (Oncotype DX, 
Genomic Health, USA) and the 50-gene assay (PAM50, NanoString, USA). Of 
the three gene assays the PAM50 shows the most promise and since its 
upbringing by Parker et al. 2009 it has been trended as the most widely used 
array30. The PAM50 in combination with IHC and proliferation parameters is 
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proving to be an effect means to classify breast tumors into one of the four 
subtypes. This is important because understanding that the tumor is basal-like 
will avoid treatment to basal-like breast cancer patients with adulterating 
chemotherapies and adjuvant therapies.  Although such tests allow for proper 
classification or at least categorization with better accuracy basal-like breast 
cancer remains a very difficult to treat disease with currently no target therapies 
available31,32.  
Triple negative breast cancer (TNBC) shares a great degree of similarity 
with basal-like breast cancer (BLBC) and is often referred to as one in the same 
because a high percentage (~80%) of BLBCs diagnose as TNBCs33. BRCA1 
mutation carriers and premenopausal African American women are frequently 
triple-negative or basal-like in origin. The frequency of BLBC in African American 
women is twice the normal occurrence and 35 times the normal occurrence rate 
in germline BRCA1 mutation carriers34. Why African American women and 
BRCA1 mutation carriers are more prone to the development of BLBC is not 
clear. Epidemiology studies are widely emphasizing a link between African 
American women and BLBC therefore more investigation is needed for a 
conclusion and currently underway. In the case of the BRCA1 mutation carriers it 
has been proposed that the loss of BRCA1 or inactivation of BRCA1 wild-type 
gene may facilitate the outgrowth of mammary stem cell population or breast 
cancer stem cell population leading to the progression of tumors with stem-cell-
like characteristics, a trait similar to the growth of BLBC35,36. Tumors of this 
subtype, BLBC/TNBCs, relapse at a higher frequency rate after conventional 
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chemotherapy and have a worse prognosis then their hormone receptor-positive 
luminal subtypes. The development of new systemic therapies is urgently needed 
as most patients with TNBC/BLBC relapse with distant metastases, and standard 
of care hormonal therapies and HER2-targeted agents are ineffective in this 
group of tumors. 28,37Broad scopes of therapeutic agents are being actively 
investigated in patients with BLBC/TNBC or BRCA1-associated tumors. 
Increased understanding of genetic or epigenetic abnormalities involved in the 
pathogenesis of BLBC/TNBC, and BRCA1-associated tumors will open up new 
discovery for the identification of new predictive biomarkers and consequent 
therapeutic possibilities for these hard-to-treat breast cancers. 
1.2. Polycomb Group (PcG) proteins and composition of the PRC2 
The Polycomb proteins (PcG) and their functional counter parts the 
Triorthax proteins (TrxG), both very essential to mammalian biology, were first 
identified in Drosophila melanogaster as transcriptional repressors and activators 
of the Hox genes, a gene family specifying cell identity along the anteroposterior 
axis of segmented animals. PcG and trxG genes have also been identified in 
vertebrates, where they also regulate Hox genes. PcG and trxG proteins are 
implicated in cell proliferation, cell migration and invasion, stem cell identity and 
lineage control, cancer, genomic imprinting in plants and mammals and X 
chromosome inactivation38,39. It is for this appreciation of their biological functions 
that PcG and trxG proteins have had great research efforts pursued to elucidate 
their mechanisms of action.  
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Four different polycomb repressive complexes (PRC) have been identified 
in mammals, including three PRC2 variants40,41, which can be seen summarized 
in Table 2. PRC1 and PRC2 can work both dependently and independently of 
one another to silence gene expression42-44. The PRC1 is thought to inhibit 
transcription through ubiquitination of H2A K119 via means of steric occlusion of 
chromatin activating components45. The PRC2 mechanism of transcriptional 
repression is invoked by methylation of H3K27 and chromatin compaction46. In 
the PRC1-dependent silencing mechanism, the H3K27Me3 mark serves to 
recruit the HPC chromodomain protein of the PRC1. The gene suppression is 
then silenced in a combination mechanism of first the PRC2 H3K27Me3 mark 
and then this histone modification  serves as a recruiting marker for the 
chromodomain containing protein, Human Polycomb (HPC), a subunit of PRC1 
complex, followed by further recruitment of the PRC1core complex, including the 
E3 ligase Ring1B for H2A K119 ubiquitination47,48. For the purpose of this thesis 
PRC1 will not be discussed in detail, but can be further reviewed in Simon, JA et 
al 2013.  
As mentioned EZH2 is the core catalytic subunit of the PRC2. There are 
two related genes sharing 65% similarity that both form PRCs, EZH1 and EZH2, 
respectively. The tissue specificity and gene silencing mechanisms are different 
for each complex containing EZH1 or EZH249.  EZH1 is predominantly expressed 
in undifferentiated tissues and non-dividing or most-mitotic tissues. The gene 
silencing of the EZH1 complex is less dependent upon the H3K27 methylation 
and more mainly dependent upon chromatin compaction. EZH2 itself is 
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predominantly expressed in proliferative tissues and plays a significant role in 
maintaining the “stemness” of undifferentiated cells. The silencing function of the 
EZH2 complex is dependent upon the H3K27 methylation capacity of the 
complex, as can be seen in by the inability to silence gene expression in cells 
expressing the SET domain deleted variant of EZH249. Despite this first report 
recent evidence suggests overlapping function of EZH1 and EZH2 in their gene 
repression pattern and silencing mechanisms therefore their interaction may be 
context specific.50 Another interesting or added complexity to the understanding 
behind the mechanism of PRC gene silencing is that of the targeting moiety EED 
splice forms,in the PRC, identified in mammalian cells. EED is important for 
targeting the PRCs to PRC target genes and it is known to exist in 4 isoforms. 
For example the PRC3 contains EED isoforms 3 and 4 and can methylate H1 in 
vitro51. This could be an in vitro artifact as no biological significance has been 
determined for this event, but an interesting observation as EED 1 and EED2 do 
not possess the ability to invoke the same in vitro methylation specificity. Addition 
subunit association with the PRC is thought to change its targeting specificity and 
silencing capacity, such as histone demethylases or long non-coding RNA 
association46,52. Other post-translational modifications have also demonstrated 
the ability to alter PRC2 gene silencing pattern and function53. 
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Table 2. Polycomb repressive complexes and their function 
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1.2.1 Genes targeted by PRC2 complex and its targeting mechanisms 
Genome wide screening approaches have been used to examine PcG 
protein (i.e.EZH2) distribution in different cell systems including Drosophila, 
mouse, and human44,46,54,55. Results show that focal association points of PcG 
proteins highly correlate with regions methylated on H3K27, and negatively 
correlates with RNA polymerase II associated genomic loci56. The area of 
association was located within core promoter regions near the transcriptional 
start sites or in regions of known transcription factor binding elements. Many of 
the promoter regions targeted by EZH2 or PcG proteins were developmental 
genes. A consensus site was not seen in mammals for areas of EZH2 binding, 
but in Drosophila, specific polycomb repressive element (PRE) sequences were 
defined56,57. Additional studies in mice showed that possibly there is a significant 
overlap of genes targeted by the PRC2 and yin and yang protein (YY1 
suggesting YY1 may help to target the PRC2 to its target loci58, but further 
validation of these studies is required. ChIP-sequencing on a genome wide scale 
in mouse ESC showed 97% of PRC2 targets correspond to CG-rich regions or 
known CpG islands. This suggests either that CG-rich regions play a role in 
PRC2 recruitment for PRC2 targeted histone methylation at these promoters and 
perhaps EZH2 and its H3K27Me3 mark have the ability to later induce CpG 
island methylation through recruitment of DNA methyltransferases to the CpG 
islands59,60. 
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1.2.2 The PRC2 in cancer progression: the role of EZH2 in BLBC  
It is know that the aberrant activity for several PcG proteins, such as Bmi1, 
SUZ12, and EZH2 are implicated in the development, progression, therapy 
resistance, and metastasis mechanisms of several different cancers, including 
breast cancer61,62. EZH2 overexpression was originally identified to be an 
oncogene in lymphoma after ectopic expression to increase tumor proliferation63. 
Since this seminal finding EZH2 overexpression has been implicated in several 
cancer types to invoke the transformation of resident normal cells, to cause 
resistance to anoikis, increase cell invasion/metastasis, promote angiogenesis, 
induce genomic instability, cause resistance to chemotherapy, induce expansion 
of the breast cancer stem cell population, and increased tumorigenesis in 
vivo64,65. The suppressor of Zeste 12 (SUZ12), a core component of the PRC2, 
essential for maintaining the methyltransferase activity and stability of EZH266,67, 
has also been shown in several to increase tumorigenesis. Knockdown by 
shRNA of either EZH2 or SUZ12 has shown to cause reduction in tumor cells’ 
abilities to proliferate, invade, and expand the sizes of the cancer stem cell 
populations64 suggesting with the above mentioned overexpression effects a 
strong line of evidence that the PRC2 functions as a bona fide oncogene through 
enhancement of many of the cancer cell dogmas described by Hanahan and 
Weinberg.  
Clinically EZH2 overexpression has shown to correlate significantly with 
tumor proliferative indexes, invasiveness, increased expression in metastatic 
tissue, and reduced overall survival with a higher reoccurrence rate68-70. Elevated 
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protein expression of EZH2 also correlates with poorly differentiated 
carcinomas71, including breast carcinoma and was reported to be a poor 
prognosis marker in triple-negative and basal-like breast cancers72-74. In a clinical 
setting poorly differentiated breast tumors contain stem or progenitor-like cell 
populations that exhibit overexpression of basal cytokeratins, vimentin, low 
surface expression of E-cadherin ,and are enriched in CD44+/CD24-  cancer 
stem cells (CSC) or breast tumor initiating cells (BTIC)28,31,37,75, which is thought 
to be derived due to the  EZH2 overexpression in these tumors76. The exact 
mechanism of how EZH2 provides for the advancement in tumor progression is 
unclear and it may not be one mechanism or silencing of one gene that causes 
the tumor progression. EZH2 has the capability of altering a complete mosaic of 
transcriptional profiling through its epigenetic transcriptional repression 
mechanisms therefore it may be a combination of silenced genes that leads to 
the EZH2-tumor promoted phenotype.  Canonical examples of EZH2 silencing of 
tumor suppressors are currently understood, one of the most notable are the 
PRC2-PRC1 transcriptional repression of the tumor suppressor locus INK4b–
ARF–INK4a. Both p15INK4b and p16INK4a act as inhibitors of the cyclin 
dependent kinases (CDKs) to control progression through the G1/S phase of the 
cell cycle, while ARF expression stabilizes and increases the function of P53. 
Thus, silencing of the INK4b–ARF–INK4a locus can promote tumorigenesis 
through different mechanisms77. Moreover the PRC2 is also known to silence the 
transcription of Rad51 and elevate Raf1 expression to induce genomic instability 
causing expansion of the breast cancer stem cell population78, silence E-
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cadherin and BRCA1 to transition cells to a more basal-like phenotype with 
increased metastatic potential76,79,80, and transcriptionally inhibit Vash1 to 
promote tumor angiogenesis81. Other tumor suppressor and metastatic inhibitors 
that are also silenced by the PRC2 include p57Kip2, RKIP, and tissue inhibitors of 
metalloproteinases82,83.  
The H3K27Me3 mark is predominantly located in the transcriptional 
binding sites of promoter regions and strongly correlates with the positioning of 
CPG DNA methylation loci. It has been proposes that by recruiting DNA 
methyltransferases (DNMT) to H3K27 methylated histones, via a chromodomain 
recognizing subunit of the DNMT complex,  CPG islands are cytosine methylated 
DNMTs. The EZH2 H3K27Me3 mark is proposed to recruit DNMT3a and 
DNMT3b. DNMT3a and DNMT3b are the de dovo DNA methyltransferases 
needed to methylate new DNA84-88. Their counterpart and maintenance DNA 
methyltransferase, DNMT1 methylates heterchromatin. Together this provides 
evidence why PcG target genes are both H3K27 methylated and cytosine 
methylated at promoter regions in human tumors89. The coordination between 
these transcriptional repression mechanisms leads to the aberrant transient and 
long-term repression of PcG target genes. 
EZH2 protein levels can be altered in cancer cells. The elevated 
expression level in turn can lead to changes in the core component composition 
of the PRCs. For example elevated expression of EZh2 can lead to the formation 
of a recently and newly characterized complex called PRC4, which core 
components consist of EZH2, SUZ12, EED2, and the histone deacteylates 
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Sirt141. This altered composition of associated proteins or PRC proteins in 
general has the ability to affect PRC targeting to differential target gene promoter 
regions through altering the composition of the PRC complexation components. 
Altering of the normal targeting of the PRCs is hypothesized to be one way 
cancer cells hi-jack the PRC to promote oncogenesis46,52,90. Aberrant up-
regulation of PRC components can be up-regulated transcriptionally by the Rb-
E2F or HIF-1 alpha pathways78,91, both common physically occurring themes in 
tumor biology. Additionally down regulation of microRNA-10192,93 can also lead to 
the promotion of EZH2 expression. Taken together these suggest and display 
transcriptional, associated subunit changing, and PTM mechanisms for 
promoting oncogeneic-PRC signaling. 
1.2.3 The PRC2: TNBC, CSC and EZH2 kinase regulated targeting   
The aggressive biology of TNBC is inferred to be the result of the 
existence of the cancer stem cell or breast tumor-initiating cell (BTIC) population, 
defined by expression of the cell-surface markers CD44+/CD24-37,94. The BTIC 
self-renewal capacity creates a cellular compartment that drives tumorigenesis 
and generates the molecular heterogeneity of breast tumors [REF]. Shown by 
many independent investigators, cell populations isolated based on 
CD44+/CD24- cell surface marker expression demonstrate the ability to form 
mammospheres or tumor spheres in vitro. In xenograft transplantation models, 
as few as one hundred CD44+/CD24- cells isolated from an existing tumor can 
generate secondary tumors that exhibit the same phenotypic heterogeneity of the 
initial tumor94. Additionally, we and others have shown that BTIC cells are widely 
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resistance to most conventional therapies94, while conventional treatment 
regiments, such as radiation and chemotherapies, can stimulate expansion or 
preferentially select for BTICs 94. Thus, translation of recent basic biology 
research on BTIC led to active clinical investigation of a broad scope of targeted 
therapeutic agents in patients with TNBC tumors for targeting the BTIC 
population 94,95.  
Stem cells are functional units of growth, repair and regeneration after 
tissue damage or loss. The stem niche protects stem cells from depletion over 
the course of the lifespan by providing a specialized microenvironment. They are 
generated and maintained in what is thought to be either symmetric or 
asymmetric division depending on the harboring tissue. As the lifespan of the 
organism increases the stem cell niche supplies the stem cells to the specific 
tissue areas needed to maintain tissue specific homeostatic balance. It is here 
that tumor or tumor stem cells may originate from cells that undergo “malignant 
reprogramming” driven by genetic and epigenetic events 96-98. The cancer stem 
cell hypothesis augments this argument by stating that malignant deregulation 
occurs in the breast stem or progenitor cell compartment, thus altering the self-
renewal program and switching the normal upper level lineage of mammary 
gland cells to BTICs of a progenitor or stem cell origin 94. This hypothesis may be 
supported in a secondary model explaining the generation of cancer stem cells 
through a dedifferentiation process of differentiated cells into cells that are similar 
to progenitor or stem cells that then can reside in the stem niche as cancer stem 
cells once they have been reprogrammed to the upper lineage cell type. Studies 
  
34 
show that BTIC gene expression profile is similar to that of the mammary gland 
during embryogenesis and early development thus BTIC are genetically similar in 
their gene expression profile to upper lineage breast cells. Epigenetic regulatory 
mechanisms are connected in a network that permits a synergistic mosaic 
regulation of specific genes, such as transcriptional programming of embryonic 
and adult stem cells that controls their self-renewal and differentiation. These 
systems indicate that generation and maintenance of BTICs can occur via 
independent or parallel mechanisms. Epigenetic mechanisms may switch these 
BTIC markers and genes “on” and “off” to generate phenotypically distinct cell 
populations with survival advantages that contribute to tumor initiation and 
progression99-101. Improved understanding of genetic or epigenetic abnormalities 
involved in the pathogenesis of BTICs will open up new therapeutic possibilities 
for these hard-to-eliminate cells, and bring new hope to breast cancer patients. 
Below, we describe some of the crucial players that regulate epigenetic 
machinery and propose that by better understanding their function specifically in 
BTIC compartment of TNBC, we will identify new therapeutic targets for 
treatment of this deadly cancer.   
The Polycomb and Trithorax groups are transcriptional repressors and 
activators that function in multimeric complexes that interact with chromatin or 
histones, leading to repressed or activated state of gene expression, respectively 
[REF].  The Polycomb Repressive Complex 2 (PRC2) initiates repression of gene 
transcription in breast and many other types of cancer via tri-methylation of 
histone 3 (H3) lysine 27 (H3K27Me)102. The core components of the PRC2 
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complex necessary for its H3K27 tri-methylation function are Embryonic 
Ectoderm Development (EED), Enhancer of Zeste 2 (EZH2), Suppressor of 
Zeste 12 (SUZ12), and Retinoblastoma-associated proteins 46 and 48 
(RbAp46/48) histone-binding proteins (REF). EZH2 serves as the catalytic 
methyltransferase component of the PRC2, adding methyl groups to H3K27 of its 
target gene promoters, silencing them102. Although EZH2 expression and H3K27 
tri-methylation are associated with an array of cancer types, little is known about 
the molecular mechanisms that control EZH2 itself, such as what extra- or 
intracellular signals induce changes in PRC2 composition or activity, how EZH2 
is targeted to specific promoter regions, or how these alterations promote 
aggressive tumor phenotypes in target tissues.  Because of its gene silencing 
properties, EZH2 is one of the key components involved in maintaining self-
renewal, pluripotency, and differentiation of embryonic and adult stem cells96-
98,100. Similarly, EZH2 is essential for tumor stem cell biology. We showed that 
expression of EZH2 sustains a reversible and undifferentiated stem cell-like 
phenotype in breast cancer cells and can contribute to their expansion through 
up-regulation of RAF1-β-catenin signaling axis 78. Furthermore, pharmacological 
inhibition of EZH2 inhibits cancer stem cell self-renewal, reduces expression of 
stem cell surface markers, and inhibits in vivo tumor initiating capacity of various 
tumors. Elevated protein expression of EZH2 correlates with poorly differentiated 
breast carcinomas and was reported to be a poor prognosis marker in triple-
negative and basal-like breast cancers74. Clinically, poorly differentiated breast 
tumors contain stem or progenitor-like cell populations that exhibit 
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overexpression of basal cytokeratins, vimentin, and low surface expression of E-
cadherin, which were all previously shown to be enriched in CD44+/CD24- BTIC 
cells36,71,96-98,100. Substantial studies highlight the role of PcG proteins, with an 
emphasis on EZH2, to maintain stemness by repressing lineage differentiation 
genes36,96-98,100. Taken with the above this suggests EZH2 and PcG proteins 
might contribute to tumorigenesis through the support and maintenance of 
cancer stem cells. The concept provides an interesting hypothesis for why tumor 
cells can appear to proliferative for a potential amount of indefinite time with 
perplexing tumor cell heterogeneity. This working model is very similar to the 
self-renewal of stem cells in tissue homeostasis or more specifically in this case, 
in tumor biology via cancer stem cells homestasis. As described above, EZH2 
expression and H3K27 tri-methylation are well studied in cancer, but knowledge 
of kinases that regulate EZH2 is limited. A few precedent EZH2 threonine (T) and 
serine (S) phosphorylation examples have been elucidated, demonstrating that 
EZH2, and in hand the PRC2, can be directly regulated through kinase 
phosphorylation, resulting in increase or decrease of EZH2 activity. Specifically, 
cyclin-dependent kinases 1 and 2 (CDK1 and CDK2) both have been 
demonstrated to phosphorylate EZH2 at T345 and promote gene silencing, cell 
proliferation, and cell invasive properties elicited by EZH2103,104. P38 kinase has 
also been shown to activate gene silencing function of EZH2 via T367 
phosphorylation and subsequent promotion of muscle stem cell proliferation105. 
Conversely, CDK1 and Akt can both inhibit gene silencing functions of EZH2 via 
its phosphorylation at T487106and S21107, respectively, thereby inhibiting H3K27 
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tri-methylation of PRC2 target genes, and reversing EZH2 oncogenic functions. 
Therefore, we hypothesize that inhibition of “EZH2 activator” kinases or activation 
of “EZH2 inhibitor” kinases is a direct way to reduce EZH2 function in BTICs. 
Known phosphorylation sites and their biological functions are summated in 
Figure 1. 
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Figure 1. The biological significance of EZH2 phosphorylation 
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1.3 Cyclin dependent kinase    
The cell cycle regulation model was derived from studies in yeast using cell 
division proteins. It was the first comparative model as there exists only one cell 
cycle dependent kinase in yeast, Cdc2 in Schizosaccharomyces pombe and 
Cdc28 in Saccharomyces cerevisiae.In either Schizosaccharomyces pombe or 
Saccharomyces cerevisiae. The cell cycle regulated by the cyclin dependent 
kinases promotes cell cycle progression by pairing with distinct cyclins at 
different stages of the cell cycle. Mammals have many cell cycle dependent 
kinases (CDK) that are grouped in family my gene homology, some are 
responsible for regulating cell cycle events through cyclin pairing and others are 
transcriptional CDKs. The mammalian cell cycle consists of four phases: (1) for 
DNA synthesis called S-phase (2) the mitotic phase called M-phase, (3) the first 
gap phase called G1-phase (4) the second gap phase called G2-phase. When 
resting cells also known as quiescent cells that rest in (G0) receive a mitogenic 
signal cell cycle progression occurs via distinct CDKs being sequentially 
activated by their partnering cyclins to drive the cell through interphase (G1, S, 
and G2) and the mitotic phase (M). The first cell cycle activation event is the 
induction of cyclin D expression (D1, D2, and D3) which commitently partners 
with and activates CDK4 and CDK6. Further progression occurs through CDK4 
and CDK6 phosphorylation of pocket proteins RB, p107, p130 and expression of 
cyclin E (E1 and E2), previously transcriptionally repressed by the Rb/E2F 
transcriptional. The increase of cyclin E in late G1 further phosphorylates and 
inactivates the pocket proteins via cyclin E coupling with and activating CDK2. 
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This allows passing through the first checkpoint in late G1 before entering S-
phase. After passing this checkpoint the cell cycle is irreversible. RB is held in its 
hyperphosphorylated status through cyclin A coupling and activation of CDK1/2 
in addition to cyclin B coupling with and activation of CDK1, with all activations 
maintained until the end of M-phase. The passing on of CDK2 activation by 
coupling with A-type cyclins, specifically cyclin A2, and activation of CDK1 
promotes the cell cycle and biological events from late S to G2 before causing 
the initiation of mitosis. The cyclin A proteins are degraded with the breakdown of 
the nuclear envelope. Then cyclin B coupling and activation of CDK1 at the G2/M 
cell cycle mark drives cells through mitosis and back to the beginning of the cell 
cycle for activation of another cell cycle process108,109. A schematic of the on 
goings of the cell cycle can be seen in more detail in Figure 2. 
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Figure 2. Cyclin and CDK activation throughout the course of the cell cycle 
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1.3.1 Cyclin dependent kinases (cdks) and cancer   
Deregulation of the cell cycle is a predominant and frequent feature in 
human cancer. Cancer cells commonly undergo (1) unscheduled proliferation, (2) 
genomic instability through increased DNA mutations and chromosomal 
aberrations, (3) chromosomal instability seen in changes in chromosome 
number. CDKs are frequent targets for aberrant cancer cell signaling108. The up-
regulation of their activity originates from genetic and epigenetic deregulation of 
both CDKs and their activator or inhibitor proteins and upstream mitogenic 
signaling.  The aberrant activation or loss of pRb is one down stream example 
resulting through CDK hyperactivation, such pRb loss has been demonstrated as 
an oncogenic event in many cancers108,110. CDK hyperactivation of can be 
initiated through abnormal expression of D (CDK4/CDK6) or E-type cyclins 
(CDK2) or loss of p16INK4a (including mutation based acquired insensitivity to 
p16INK4a) possibly, as elduded to before, through EZH2-dependent gene 
silencing. Abnormal overexpression of cyclin E and downregulation or loss of 
CDK2 inhibitors p21 and p27 are also frequently observed in many tumors, but 
interestingly follow-up genetic experiments indicate that CDK2 does not play a 
significant role in cells lacking p21 or p27.Iit is thought that because p21 and p27 
can also inhibit CDK1 that in these tumors tumorigenecity is due to deregulation 
of CDK1 and not CDK2 thus demonstrating a role for CDK1 activation driving 
tumorigenecitiy. Cyclin E overexpression does still drive the tumor development 
and progression of highly aggressive tumor phenotypes. In the case of the cyclin 
E overexpression tumors, both long and short forms, the tumors are dependent 
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on CDK2 function. This demonstrates that aberrant activation of each respective 
CDK has the ability to promote tumor development with proposed different 
driving mechanisms and tumor promotion under different contexts For example 
emerging studies suggest cancer cells may have specific utilization for different 
CDKs. CDK4 is dispensable for mammary gland development, but is needed for 
promoting breast cancer development dependent upon Erbb2, Hras or Myc 
oncogenes108,110.  
The constitutive and aberrant activation of CDKs has the ability not only to 
contribute to increased tumor cell proliferation but also to genomic 
instability108,110. In turn alteration of DNA damaging signaling pathways and 
response, and mitotic check points, frequently leads to elevated CDK activity. 
Despite the complexities and difficulties they cause for developing treatment 
strategies and drugs based on CDK context specificities and structural 
similarities.  CDK based therapy strategies have treatment potential. Design of 
the treatment regimen plans should take into consideration the CDK biology of 
the tumor being treated. 
1.3.2 CDKs, adult normal stem cells and cancer stem cells 
Adult stem cells are in a constant fluctuation of steady-state dormancy and 
activation phases based on the tissue niche’s homeostatic need to repair 
damaged tissues or to provide growing tissue with differentiated lineage specific 
cell supply. The fluctuation between these states as well as the production of 
new stem cells through symmetric or asymmetric division requires delicate 
control. Releasing stem cells from their quiescent state to enter the cell cycle 
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without checkpoint controls would exhaust the stem cell population and inhibit the 
stem cell exhausted tissue from repairing cell damage or from providing new 
growth capabilities. Thus, cell cycle regulation is essential for maintain stem cell 
homeostasis in native tissues96-98.  The balance between CDKs and their 
inhibitors have been determined to be crucial for maintaining both stem cell and 
progenitor cell populations. CDK deficient activity may cause for a limited stem 
cell population incapable of tissue upkeep while aberrant activity may induce 
expanded stem cell populations leading to genomic instability, genetic or 
epigenetic hits and consequent tumorigenic events. Studies demonstrating 
CDKs’ roles in stem cell biology are mentioned below. For example animal 
studies demonstrate redundant effects of CDKs in maintaining the self-renewal 
capacity of neural progenitor cells. In this model, CDK2 deficiency was shown to 
cause differentiation an effect synergized through pharmacological inhibition of 
CDK4.  CDK influence on stem cell biology can be seen in other adult stem cell 
models exemplified through regulation of known CDK inhibitors or CDK inhibitor 
(CKI) protein familes, INK4 and Cip/Kip. Embryonic stem cells also have their 
renewal-capacty tightly regulated by CDK activity, CDK2 specifically. Taken 
together this suggests multiple CDK involvement occurs in multiple stem cell 
models, including embryonic, adult, and progenitor cells. These parallel systems 
provide model for tumor stem cell and progenitor cell biology therefore put 
forward a suggestive role of CDK involvement and significance in upper lineage 
tumor cell homeostasis96-98,108,110. Furthermore, the CKI protein families are 
tightly regulated by stem cell maintenance and are involved in promoting 
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signaling pathways of Notch and TGFβ/SMAD, known stem cell promoting 
pathways, suggesting a true hiearchy of cell control of CDK activity in the stem 
cell niche. The deregulation of this checks and balance system may cause 
deviation of normal stems to later become cancer stem cells through aberrant 
signal transduction mechanism. Once the cancer stem cells reside in the tissue 
stem cell niche they benefit from the niche’s provided protection and can 
replicate indefinitely to arm one cancer cell with the molecular complexity, 
heterogeneity, and support to promote tumor development. CDKs may in fact 
present a therapeutic intervention point to target the cancer stem cell population 
in certain cancer types with dependency on that specific CDK.  
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CHAPTER 2. STATEMENT OF OBJECTIVE 
BRCA1 inherited mutation carriers have been shown to be almost %90 
basal-like breast cancer (BLBC) in tumor origin. This is unique because very little 
is known, other than BRCA1,about what mechanism drives the development of 
BLBC. Often BRCA1(albeit possibly set apart from other basal-like breast 
cancers that do not harbor the BRCA1 mutation) is used as the best known 
model system for basal-like breast cancer. Suggestive of similarities between 
BRCA1-derived BLBC and sporadicBLBC, both are predominantly triple-
negative, as can be seen by their lack of expression for the estrogen, 
progesterone, and HER2 receptors in IHC immunohistochemical staining and 
similar in their gene expression profiles. As mentioned previously nearly %80 of 
BLBCis diagnosed as TNBC.  
The function of EZH2 recently has been linked to BLBC or TNBC through 
reports showing EZH2 correlations with undifferentiated breast cancer and as 
poor prognostic marker in BLBC. Moreover EZH2 was found to decrease BRCA1 
expression, observed to be overexpressed in human tumors and mouse tumor 
models that are BRCA1-deficient, and dependent for the survival of BRCA1-
deficient cancer cells. Knowing BRCA1 loss drives cancer by promoting the 
expansion of aberrantly tumorigenic upper lineage breast cancer cells with 
similar genetic profiles as sporadic BLBC the above mentioned evidence is 
suggestive of EZH2 playing a role in modulating the biology of BLBC by one of 
two ways (1) by maintaining cells in a non-differentiated state or (2) through a 
process of de-differentiation most likely through EZH2-PRC2 dependent function. 
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Each model strikes similarity to the proposed model for the generation of stem 
cells or breast cancer stem cells, which in 2011 Chang et al. demonstrated EZH2 
directs the expansion of the breast tumor initiating cell (BTIC) population. 
  Cyclin E/CDK2 also relatedly demonstrates involvement in BLBC.  High 
cyclin E expression is observed in BRCA1 mutation carriers and the high 
expression Cyclin E negatively correlates with poor survival of the BRCA1 
mutation carrier patients. CDK2 being the only known catalytic partner of the 
Cyclin E/CDK2 complex demonstrates that the elevated cyclin E levels is also 
associated with increasing CDK2 activity, which is further supported by not only 
high expression level of cyclin E in BRCA1-derived BLBC, but also the loss of the 
CDK2 inhibitor protein, p27, in these tumors. The elevation in CDK2 activity 
being important for basal-like breast cancer can most directly be observed in an 
MMTV mouse model expressing a constitutively active CDK2 and its ability to 
generate mammary tumors with a basal-like signature or component. This data 
suggest that CDK2 activity may play a biologically significant role in BLBC.   
EZH2 has been shown to be transcriptionally Rb/E2F up-regulated 
duringthe cell cycle. EZH2 peak expression during the cell cycle occurs at the 
G1/S transition checkpoint. At this same stage of the cell cycle CDK2 activity also 
peaks due to a rise in cyclin E expresson and has continuous activity until the 
G2/M transition via complexation with A-type cyclins. EZH2 has previously been 
shown to be regulated by CDK phosphorylationin a cell cycle dependent manner 
on residues T345 and T487. This suggests that PRC2 activity, including EZH2, 
can be modulated through deregulation of the cell cycle, specifically through 
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CDK2 activity. Such aberrant PRC2 activity is synonymous with maintaining 
undifferentiated cell states similar to BLBC gene signatures, increased pools of 
cancer stem or progenitor cells and coincidently aggressive tumor traits 
representative of BLBC. Understanding the underlying signaling events that 
generate the development of or maintain the biology of BLBC will provide insight 
into the development of rationalized targeted therapies to for mammary 
oncologist to provide for BLBC patients 
Rationale 
 Basal-like breast cancer is the most difficult to treat breast cancer sub-
type with very few adequate biomarkers available to predict patient survival or 
therapeutic response. . It is known that independently of each other both cyclin E 
and EZH2 overexpressi in basal-like breast cancer and are markers of poor 
prognosis. Further linking the two proteins, EZH2 expression level has also been 
reported to be highest during the G1/S phase of the cell, which coincidently is the 
cell cycle stage where cyclin E/cdk2 activity is the most robust. Knowing 
previously that EZH2 has been implicated in the downregulation of BRCA1 and 
E-cadherin, known events leading to the development of a more basal-like breast 
cancer phenotype, and that EZH2 can be regulated by CDK phosphorylation, we 
asked if cyclin E/cdk2 may regulate EZH2 to (1) modulate EZH2 function and (2) 
increase breast cancer tumorigenecity in a manner similar to a tumor 
representative of basal-like breast cancer and (3) does the EZH2 
phosphorylation correlate with patient survival trend. 
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Figure 3. Triangle hypothesis of cyclin E/Cdk2 regulation of EZH2 function 
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Hypothesis  
The cyclin E/Cdk2 complex phosphorylates EZH2 at evolutionary 
conserved CDK2 phosphorylation consensus site causing an increase in 
the tumorigenecity of breast cancer cells capable to generate a more 
aggressive tumor phenotype with enhanced basal-like breast cancer 
characteristics. We propose this occurs through modulation of EZH2 
canonical oncogenic functions. 
Below are the specific aims for testing the above mentioned hypothesis: 
Aim 1: Investigate the pathological correlation between cyclin E/CDK2 and 
EZH2 in triple negative breast. 
Cyclin E/CDK2 and EZH2 each have recently been shown to correlate 
with poor patient prognosis in basal-like breast cancer, but the co-expression, 
suggestive of modulation between the two, has yet to be determined. To 
investigate if there is clinical significance in triple-negative breast cancer (TNBC) 
between E/CDK2 and EZH2 cyclin tissue microarray cohorts of TNBC and non-
TNBC biopsies will be evaluated for cyclin E and EZH2 expression by 
immunohistochemical staining. Potential cyclin E/CDK2 protein-protein 
association will be evaluated endogenous using co-immunoprecipitation in 
candidate TNBC cell lines and in vitro. Phosphorylation of EZH2 serine or 
threonine amino acid residue will be mapped to EZH2 functional domains based 
on using in vitro kinase mapping assay. Identification of the serine or threonine 
residue in vitro will be confirmed by generation of a custom phospho-antibody. 
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Aim 2: Investigate the clinical significance of EZH2 phosphorylation.  
 In order to investigate the clinical significance of the EZH2 serine or 
threonine phosphorylation sites, a custom antibody will be generated recognizing 
the phosphorylation site suitable for IHC. Tissue microarray cohorts of TNBC and 
non-TNBC biopsies will be immunohistochemical stained using the custom 
phospho-EZH2 antibody and survival data will be compared with EZH2 
phosphorylation levels to determine if patient overall survival decreases with 
increasing EZH2 phosphorylation levels. Supportingly, cyclin E expression levels 
will be analyzed to determine if Cyclin E elevated expression correlates with 
elevated EZH2 phosphorylation levels. 
Aim 3: Elucidate the cell cycle dependency and biological function of cyclin 
E/CDK2 phosphorylation of EZH2.  
 To examine if EZH2 phosphorylation is cell cycle dependent, TNBC 
candidate cell lines will be synchronized in G1/S of the cell cycle or G2/M of the 
cell cycle using double-thymidine or nocodazole block, respectively.  After 
release from cell cycle synchronization, phosphorylation of EZH2 will be 
monitored using SDS-PAGE analysis over a 14 hour window (i.e via immunoblot 
with the custom phosphor-EZH2 antibody). Examination of cells held in G1/S or 
G2/M compared with unsynchronized cultured TNBC cells will determine if EZH2 
phosphorylation is enhanced in either specific stage of the cell cycle. EZH2 has 
been implicated previously to TNBC in clinical patient samples and in the 
expansion of the BTIC population [REF], but how this alters the functional 
phenotype of TNBC or affects BTIC in TNBC has yet to be determined. To 
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evaluate this role of EZH2 phosphorylation stable TNBC cells lines using 
lentivirus infection will be generated in each of the respective TNBC cells 
consisting of vector, EZH2-wild type, and the threonine phosphorylation site 
mutated to alanine. Functional in vitro assays for canonical EZH2 oncogenic 
function such as (1) cell proliferation using Brdu (2) migration/invasion using 
boden chambers and matrigel coated boden chambers (3) anchorage 
independent growth using soft-agar, and (4) angiogenesis hMEC tube formation 
(5) BTIC regulation using mammosphere assay will be used to compare the 
panel of the abovementioned cell lines to elucidate whether the role of 
phosphorylation plays an enhancing or diminishing role in regulating the 
canonical oncogenic functions of EZH2. In addition mammospheres generated in 
the above mentioned panel may not demonstrate change in CD44hi/CD24lo cell 
populations so alternate cell surface markers for tumor progenitor cell markers 
will be assed including EPCAM, CD49f, and CD133. In addition aldefluor assay 
will be used to determine the relative level of ALDH1 activity thus the relative 
level of tumorigenic capacity of each of the respective TNBC lines in the in vitro 
spheres to further characterize the cell marker studies. Similarly, in order to 
delineate direct role of EZH2 phosphorylation from CDK kinase function or  the 
phosphorylation causing direct loss of global EZH2 function the above mentioned 
functional assays 1-5 will be performed in TNBC cells that have had established 
lentiviral knockdown of the CDK of interest determined in Aim 1 and, 
independently, EZH2 lentiviral knockdown. The in vivo tumorigenic capacity of 
EZH2 phosphorylation, whether it be diminishing or enhancing of wild-type EZH2,  
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will be determined by injection of 1.0x106 TNBC cells from the panel described 
above, including the shLuc, shCDK and shEZH2 controls, into the mammary fat 
pad of female nude mice. Each respective cohort will consist of 10 mice with 
each mouse of the cohort injected with the same number of the indicated cell 
line; (1) shLuc (2) shCDK (3) shEZH2 (4) vector (5) EZH2 wild-type (6) EZH2-
T/A. The in vivo growth of the tumors will be determined by tumor palpitation to 
determine tumor volume. In addition tumor weight and size will be determined.  
Aim 4: Determine potential for designing a therapy regimen for reducing 
the effects gained through cyclin E/CDK2 phosphorylation of EZH2 
 As TNBC is a very difficult to treat disease with currently very limited 
target therapies available, gathering an understanding of molecular mechanisms 
driving the aggressive nature of TNBC tumor development provides a venue to 
develop targeted therapies against such said pathways for better treatments of 
TNBC.  To determine if clinical trial drugs such as CDK2 inhibitor, SNS032, or 
EZH2 specific inhibitors, such as GSK1206, have the ability to inhibit the 
development of TNBC tumors a tumor sphere assay will be developed by 
culturing TNBC cell lines in sphere promotion forming media. Because spheres 
represent the functional perspective of tumor initiating cells such a sphere assay 
will model cells with the potential mimic of in vivo therapeutic resistance. If the 
therapy regimens works in a tumor sphere assay it should be applicable later in 
more rigorous pre-clinical therapy models. Efficiency of the therapy administered, 
whether SNS032 or GSK1206 will be determined by counting the relative number 
of spheres before treatment compared to the relative number of spheres after 
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treatment and referenced with a sphere viability index determined by staining 
spheres with proliferation markers such as BRDU or MTT cell stain applied in  
culture.
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 CHAPTER 3 MATERIALS AND METHODS 
3.1. Antibodies, reagents, chemicals, and drugs 
Antibodies from their respective places of purchase are mentioned below. EZH2, 
H3K27Me3, Histone 3, Cdk2, phosho-CDK2, NPM, or phospho-NPM was 
purchased from Cell Signaling. Cyclin E and Cyclin B1 antibodies were obtained 
from Santa Cruz and Neomarkers respectively. FACS antibodies were from BD 
Biosciences excluding the EPCAM FACs antibody, which was purchased from 
Biolegend. Protein A, protein G, and glutathione Sepharose beads used in 
immunoprecipitation were ordered from Amersham Biosciences.  Cell culture 
supplements such as Heparin and Cortisozone were used in mammosphere 
culture assay were from Stem Cell Technologies Inc.  Polybrene for lentiviral 
transduction into cultured cell lines was purchased from Millipore. Assays for 
measuring cell migration/invasion coated with basement membrane in the case 
of invasion plates were purchased from BD biosciences. Soft agar assay plates 
were made in-house using Bio-Rad agarose with low melting point. All other 
tissue culture plates were purchased from Corning. [γ32p] ATP (4500 Ci/mmol) 
was from MP Biomedicals. Small molecule inhibitors for CDK2 or EZH2 such as 
roscovitine or DzNep A were purchased from Cayman Chemicals. CDK2 
inhibitor, SNS032, was purchased from Selleck Chemicals and EZH2 inhibitor 
GSK343 or GSK126 were purchased from GlaskcoSmithKline. 
3.2. Cell culture 
Cell lines used were all purchased from ATCC and were subjected to and 
validated using DNA fingerprinting. Cell lines used included: MCF-7, a human 
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mammary adenocarcinoma cell line isolated from pleural effusion; T47D, a 
human mammary ductal carcinoma cell line isolated from pleural effusion; 
ZR751, a human mammary ductal carcinoma cell line isolated from ascites; BT-
549, a human mammary ductal carcinoma originated cell line; MDA-MB-231, a 
human mammary adenocarcinoma cell line from isolated from pleural effusion 
HS578T, a human mammary carcinoma originated cell line; and 293T, a human 
embryonic kidney cell line. Cell lines were cultivated in Dulbecco’s Modified 
Eagle’s Medium/F12 (1.5 g/L Glucose) or Dulbecco’s Modified Eagle’s Medium 
supplemented (4.5 g/L Glucose)  with 10% heat-inactivated fetal bovine serum 
(FBS), Penicillin/Streptomycin (100U, 100µg/ml) at 37oC in a humidified 
atmosphere with 5% CO2. Neomycin-resistant stable cell lines were kept in G418 
(500µg/ml) in addition to above specified conditions. Puromycin-resistant stable 
cell lines were kept in puromycin (2.5µg/ml) in addition to the above base-line 
culturing conditions. 
3.3. Transfection 
1 x106 cells were seeded on each plate for transfection in 100mm culture dish 24 
hours before transfection. A 1:1 (w/v) ratio of plasmid DNA and to liposome were 
mixed and diluted in 200µl OPTI-medium at room temperature for 30mins after 
gentle vortexing. The full serum medium in each dish was changed to 3m OPTI 
Medium 30 mins before adding transfection mixture. The plasmid DNA:liposome 
mixture was then added into  the cell culture dish with gentle side-to-side 
agitation for mixing. After 4-6 hours of incubation in the tissue culture incubator, 
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the medium was changed back to normal 10% FBS medium conditions and 48 
hours later the transfected cells were used for experiment or harvested.  
3.4. Clonal stable line selection 
pCDNA3 constructs of 3xmyc-EZH2 wild type (3XMycEZH2-WT), 3xmyc-EZH2-
T416A (3XMycEZH2-T416A),T416A and ), 3xmyc-EZH2-T416D (3XMycEZH2-
T416D) were transfected into MCF-7 or MDA-MB-231 cells as aforementioned. 
After 48 hours 1 x105 cells were subcultured into complete media containing 
500µg/ml G418 in order to provide for clonal selection. Approximately 2 weeks 
later distinct cell colonies were isolated, and expanded as representative single-
cell pools. These single-cell pools were tested for EZH2 expression and 
cryopreserved at -80C. 
3.5. Western Blot 
3.5.1. Cell lysis 
Cell culture dishes were washed with cold PBS buffer 2X and then lysed with 
cold modified RIPA lysis buffer (150 mM NaCl, 1% NP-40, 0.5% Triton-X100, 
0.1% SDS, 50 mM Tris at pH 7.5, 25 mM NaF, 2 mM Na3VO4, 5 mM PMSF, 2 
μg/ml aprotinin). Cells were then harvested with cell scraper and this early 
process whole cell lysate was sonicated briefly for 30sec 2X at low power. 
Lysates after sonication were then “cleared” via centrifugation. Lysate 
concentration was determined by BCA protein assay (Pierce). 
3.5.2. Immunoblotting 
Equal amounts of total protein in equal volumes were diluted with 6x SDS-DTT, 
denatured by boiling  for 10min at 100oC, loaded into 6-12% SDS-polyacrylamide 
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gels (SDS-PAGE). Gel electrophoresis was ran at slow speed of 80V or fast 
speed of 180V. Electrotransfer was then performed onto PVDF membranes on 
ice at 0.300MA for 90min. The PVDF membranes were then blocked with either 
5% bovine serum albumin (BSA) or non-fat milk dissolved in PBS for 1hr at room 
temperature. Blocking buffer was then washed to avoid particulate build up on 
the PVDF membrane by washing in PBS for 15min at room temperature. Specific 
primary antibodies were added at dilutions specified by the commercial antibody 
provider overnight at 4C. After overnight incubation, PVDF membranes were 
washed for 30min in PBS at room temperature then incubated with species 
specific horseradish peroxidase-conjugated (HRP) secondary antibody at a 
1:5000 dilution for 1hr at room temperature. Following secondary antibody 
incubation PVDF membranes were washed in PBS for 1-3hr at room temperature 
or until specific band resolution was as desired in reference to background 
signal. The immunoblots were incubated with enhanced chemiluminescence 
(ECL) kit solutions after ECL1 and ECL2 mixing for 2min. Visualized signal was 
detected by developing on autoradiography film.  
3.6. Immunoprecipitation 
Immunoprecipitation reactions were carried out using an antibody to protein 
lysate ratio of 5ug:1mg (i.e. 5ug EZH2 antibody). Whole cell lysate was first 
“cleared” for non-specific interaction with sepharose beads via a 4-6hr incubation 
at 4C. Whole cell lysates were then subjected to incubation with target antibody 
overnight at 4C following next  day incubation with 50ul of protein A or protein G 
per 1mg whole cell lysate  for 4-6hr at 4C. The immunoprecipitated complex was 
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washed five times with PBS, suspended in equal volume of 2X SDS-DTT protein 
sample buffer, and denatured at 100C for 10min. SDS-PAGE and immunoblot 
were then used to analyze interacting proteins 
3.7. Kinase assay 
3.7.1. EZH2 truncation cloning 
Three EZH2 truncations (domain I, domain II, domain III) were made in order to 
express EZH2 truncation fragments in GST N-terminal fusion protein format. 
EZH2 GST-N-terminal protein fragment domain I was from amino acid residues 
1-333, domain II from amino acid residues 334-610, and domain III from amino 
acid residues 611-746. cDNA coding regions for the three respective domains 
were subcloned in pGEX-6P1 between restriction digest sites of BAMH1 and 
Xho1. Primers used for subcloning can be seen in Table 4.  
3.7.2. Site-directed point mutatgenesis of GST-EZH2 truncation fragments  
Site-directed point mutatgenesis was performed on the EZH2 cDNA mentioned in 
3.6.1. Domain II subcloning primers were then used to PCR amplify domain II 
cDNA for later t4 ligase mediated ligation into the PGEX-6P1. 
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Table 3. Primers for constructing GST-EZH2 deletion fragments and T416 
mutants. 
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3.7.3. IPTG induced E.Coli expression of GST-EZH2 protein fragments 
GST-EZH2 truncation fragments were expressed and extracted from BL-21 
competent E. Coli cells. Transformed BL-21 cells were grown on ampicillin 
resistant LB-Agar plates to form single colonies. Each representative colony for 
each specific GST-EZH2 fragment was then grown overnight in LB broth with 
100ug/ml ampicillin at 37C and at 250rpm. The overnight culture was then diluted 
into LB broth the next day at a 1:50 dilution factor and grown at 37C until an 
OD .300-.600 was obtained, where then 0.1mM IPTG was added for 4hrs at 37C, 
all at 250rpm. Culture flasks were then moved to room temperature incubation 
and shook vigorously until pellets were harvested the next day by centrifugation 
at 6000rpm. Pellets were lysed in 20% sarkosly detergent solution, sonicated 
until viscosity reduced, and GST protein was extracted from the supernatant by 
incubation with GST-sepharose beads overnight at 4C. GST-EZH2 proteins were 
eluted from the sepharose beads using 50mMM reduced glutationine solution pH 
8.0. Eluent was gel-filtered, used size appropriate gel filtration centrifugation 
columns from Millipore. 
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3.7.4. in vitro kinase assay 
GST proteins (i.e.GST-EZH2 variants) were isolated and purified as described in 
3.7.3. Buffer exchange was performed to store eluted GST proteins in 20mM 
Tris-HCl PH 7.4. Approximately 1ug of eluted GST protein was mixed with 0.2ul 
purified cyclin E/CDK2 kinase complex purchased from Millipore in kinase buffer 
(60 mM HEPES at pH 7.5, 5 mM MgCl2, 5 mM MnCl2, 3 µM Na3VO4 and 1.25 mM 
DTT) in the presence of 1 µCi γ32P ATP at 37°C for 30 min. SDS-DTT protein 
sample buffer was then added to the reaction and samples were denatured for 
10min at 100°C. Samples were then analyzed by SDS-PAGE, stained with 
coomassie to determine protein loading, and incubated with film for overnight or 
for appropriate time at -80°C to determine phosphorylation levels. 
3.7.5. in vitro S35 labeling and pull-down 
Recombinant GST-EZH2 proteins prepared as described in 3.7.4 were incubated 
with the in-vitro transcribed and translated product HA-CDK2, which was 
produced using a TNT coupled reticulocyte lysate system from Promega. 
Incubation occurred in binding buffer for 1hr at 4°C. Rabbit IgG antibody or anti-
HA antibody was then added after incubation at 4°C for overnight 
immunocomplexing. The product from the pull-down assay was washed 
extensively with binding buffer or PBS, and the bound proteins were eluted with 
SDS-DTT protein sample buffer for later SDS-PAGE analysis. 
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3.8. Viral shRNA infection  
3.8.1. Production of lentiviral particles  
Plko.1 vector based shRNA constructs were purchased from Acdemic Sinica, 
Taiwan. Respective EZH2 shRNA constructs were designated shEZH2 #3 and 
shEZH2 #4 (3’-UTR). Respective CDK2 shRNA constructs were designated 
shCDK2 #587 and shCDK2 #590 (3’-UTR). The control knockdown construct 
used to ensure any non-specific or off-target knockdown was a luciferase shRNA 
designated shLuc. To form lentivirus particles VSV-G, ∆R89.1, the respective 
plko.1 shRNA plasmids were transfected to 5.0x105 293T cells, seeded in 10cm 
dishes 12hr before transfection, as previously mentioned in methods section 3.1. 
The plasmid transfection ratio was 6:4:1, respectively. 6hrs after transfection, 
opti-medium was changed to 1% BSA containing 10% medium. Viral 
supernatants were then concentrated using lentiviral concentrator-X from 
Clonetech after centrifugation, aliquoted, and stored at -80C.     
3.8.2. Virus infection and polyclonal stable line selection 
Prior to virus infection, target cells were seeded based on their growth rate in 6 
well dishes, roughly to a cell number of 2.0 x105 cells. Target cells were then 
incubated with 100ul of aliquots described in 3.8.1. and 1.5ml-2.0ml of 10% 
medium after 1hr centrifugation at 2500rpm. Each infection reaction was 
supplemented with 8ug/ml polybrene/DMSO from Millipore. Cells were incubated 
for 24hrs and medium was changed to 10% FBS medium or to a second viral 
transduction. After primary infection, puromycin was added to a concentration of 
1ug/ml at approximately 72hrs for selection of polyclonal cell populations. 
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Puromycin selection occurred for 1 week and puromycin supplementation was 
replace every 3 days. Polyclonal stable lines were then analyzed by SDS-PAGE 
and cryopreserved in liquid nitrogen for future experiments.  
3.9. Immunohistochemical (IHC) staining 
IHC staining was performed using a immunoperoxidase-based staining method 
via a AEC detection kit from Pierce. Tissue microarray (TMA) slides were 
prepared from the respective breast cancer patient paraffin-embedded cohort 
5uM sections. Paraffin embedded sections were deparaffinized in xylene 
followed by serial rehydration using ethanol dilution gradients. Antigen recovery 
was achieved by microwaving samples for 8min in 10 M sodium citrate buffer PH 
6.0 followed by room temperature incubation for 30min and 2X was in PBS. The 
slides were then trypsinized using 0.05% trypsin in PBS at room temperature for 
15min followed by 3X wash in PBS (each wash being 5min). Endogenous or 
basal level peroxidase activity was reduced by an addition of 0.3% H2O2 in 
methanol for an incubation period of 15min at room temperature followed again 
by 3X wash in PBS (each wash being 5min). The slides were then blocked with 
10% serum corresponding to the species of the primary antibody in PBS in a 
humid chamber at room temperature for 30min. The residual serum was blotted 
with chem-wipes. The primary antibody was applied to the slides and incubated 
overnight at 4C.  Slides were washed the next day 3X in PBS then incubated with 
biotin-conjugated secondary anti-mouse or rabbit IgG for 1hr at room 
temperature. The avidin-biotin-horseradish peroxidase complex from Vector Labs 
was applied after being washed 3X in PBS. The avidin-biotin-horseradish 
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peroxidase complex was incubated for 1hr at room temperature followed by 3X 
PBS wash. Antibody signals were then detected by -ethyl carbazole chromogen 
kit (AEC) chromogen substrate kit from Pierce. The slides were counterstained 
with Mayer’s hematoxylin and mounted in aqueous mounting from Lerner 
Laboratories. Finished slides were then visualized and evaluated under 
microscope by both lab pathologists and processed for final statistical analysis.  
3.10. Chromatin immunoprecipitation (ChIP) assay 
Cells were fixed with 5% formaldehyde for 10 min, washed, and lysed in cell lysis 
buffer (5 mM HEPES [pH 8.0], 85 mM KCl, 0.5% NP-40) for 30min at 4C. 
Fixation was stopped using 5M glycine addition. Cells were then lysed in 
modified RIPA buffer and the lysate sonicated on ice to achieve DNA 
fragmentation of approximated 500-1000bp. The supernatant was diluted 10-fold 
with dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM 
Tris-HCl pH 6.8, and 167 mM NaCl). Chromatin immunoprecipitation was 
achieved by adding 5μg of target antibody to 1mg of protein lysate overnight at 
4C. Protein/DNA immunocomplexes were then pulled down by protein A/G-
conjugated agarose beads. The beads were washed with wash buffer (0.1 M 
sodium phosphate buffer PH 6.8, 0.1% Tween-20) for 3X, and the bound protein 
was eluted twice with 30 μl 0.1 M citrate PH 3.0 and pooled. Extraction buffer  
(0.1% SDS, 50 mM NaHCO3, 5 μl of 10 mg/ml RNase, 18 μl of 5 M NaCl) was 
added to elute the protein from the DNA and incubated at 65°C overnight to 
digest residual RNA. The retrieved DNA was purified with a Qiagen miniprep spin 
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column and eluted in water. The promoter regions were amplified by 
conventional PCR or qRT-PCR.  
3.11. Real time RT-PCR 
RNA was extracted from cells of interest using a Qiagen RNeasy kit. The first 
strand synthesis was performed to convert RNA to cDNA using Bio-Rad first 
strand synthesis kit and qRT-PCR was performed as previously described. The 
gene expression was compared relatively to 18s rRNA.  
3.12. Colony formation assay 
Cells were seeded in ranges of 500, 1000, and 5000 cells per well in a 6 well 
dish and grown for 10 days in 10% FBS medium. Colony formation was 
assessed via fixation, crystal violet staining for 5min, followed by overnight wash 
in PBS or water. Colonies were counted under microscope for quantitation. 
 
3.13. MTT cell proliferation assay 
Cells were seeded at 1.0X104 and grown in 10% FBS medium. Each day MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)  was added to cells 
and incubated for 4-6hrs. The insoluble formazan salt was dissolved using 
DMSO the optical density and was determined at 570nm. 
 
3.14. Soft-agar anchorage independent growth assay 
50,000 cells were seeded in 12 well plates in top layer 0.25% agarose on 
top of base layer of agarose composition of 0.5% agarose. Agarose layers 
were both supplement to 10% FBS medium. Cells were grown for 6-8 
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weeks with every second-day fresh 10% medium being added to the dish. 
After 8 weeks visible colonies were stained with crystal violet for 5min and 
washed overnight with PBS. Colonies were counted and visualized under 
light microscope for quantitation.  
3.15. Migration assay 
Migration was measured in 24-well migration chamber plates with a 8µm pore 
size polycarbonate filter purchased from BD Biosciences. The lower chamber 
contained 0.75ml of 10% FBS medium. The upper chamber contained 1.0X104 
cells seeded in serum-free medium. Cell migration was carried out for 24hrs in 
cell incubator. After migration, the filter was fixed with 4% glutaraldehyde in PBS 
and stained with crystal violet. Unmigrated cells were removed from on top of the 
filter with a cotton swab. Migrated cells were then counted under microscope for 
quantitation after destain. 
3.16. Invasion assay 
Invasion was measured in 24-well migration chamber plates with a 8µm pore size 
polycarbonate filter coated with growth factor free matrigel purchased from BD 
Biosciences. The lower chamber contained 0.75ml of 10% FBS medium. The 
upper chamber contained 5.0X104-1.0X105 cells seeded in serum-free medium. 
Cell migration was carried out for 24hrs in cell incubator. After migration, the filter 
was fixed with 4% glutaraldehyde in PBS and stained with crystal violet. 
Unmigrated cells were removed from on top of the filter with a cotton swab. 
Migrated cells were then counted under microscope for quantitation after destain. 
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3.17. Anoikis Assay 
6 well-tissue culture dishes were pre-coated with poly-HEMA concentration of 
5mg/ml at 37C and was 3X with PBS before seeding cells. 5.0X105 cells were 
suspended in each well in culture medium containing 0.5% methylcellulose. Cells 
were stained with ethidium bromide homodimer and calcein-AM, both from 
molecular probes for 30min at 37°C to determine apoptotic and viable cell 
populations, respectively. Fluorescent signal was detected and quantified under 
microscope. 
3.18. Mammosphere assay 
Breast cancer cells were grown to confluence of 80-90% in a 2-D monolayer in 
10% FBS medium. Cells were then trypsinized, washed 3X in PBS, and 
suspended in Stem Cell Technology, Inc. complete Mammocult medium for later 
seeding in non-adherent 12-well culture dishes at seeding density of 1.0X104 per 
well. Sphere formation was then assessed at day 7 or day 10. Inhibitor addition 
was performed after normalizing sphere seeding to 100 spheres for each well 
treated with inhibitor. 
 
3.19. 3-D growth assay 
Cells were grown to 80-90% confluence, trypsinized, washed in PBS, and 
harvested or suspended in harvesting buffer from Trevigen. Cells were then 
seeded to 3.0X103 per well, with addition of 3-D Culture Cell Proliferation 
Reagent to each well according to Trevigen assay protocol. Cells were then 
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incubated at 37°C, 5% CO2. Inhibitors were added to spheres at day 2 at 
assessed concentrations from mammosphere assay. 
 
3.20. Xenograft mouse model 
Tumorigenesis assays were performed in an orthotopic breast cancer mouse 
model. MDA-MB 231 cells (2.0 x 106) with lentiviral-stable expression of vector, 
EZH2WT, EZH2T416A, EZH2T416D, shLuc, shCDK2 #587, or shEZH2 #4 were 
injected into mammary fat pads of nude mice (n = 5 per group). Tumor size was 
measured every 3 days with a caliper and tumor volume was determined using 
the formula: L x W2 x 0.52, where L is the longest diameter and W is the shortest 
diameter. 
3.21. Statistical analysis 
SAS software (version 8.1) was used for statistical analysis (SAS Institute). A 
univariate analysis was used to determine the variable distributions. Categorical 
variables among the groups were compared with the χ-squared test or Fischer’s 
exact test if 20% of the expected values were smaller than five. Continuous 
variables were analyzed using the Student’s t-test. A p-value of <0.05 was 
considered statistically significant. 
. 
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CHAPTER 4. RESULTS 
4.1 Defining the clinical significance of EZH2 and Cyclin E co-
expression 
 The current clinical understanding in breast cancer oncology regarding 
basal-like breast cancer (BLBC) tumors and triple-negative breast cancer (TNBC) 
tumors is that they share a similarity determined by gene expression analysis 
and key biomarker expression. Overall 80% of BLBC are considered to be triple-
negative (TN) in status based  on IHC negative staining for estrogen-alpha and 
progesterone receptor, and lack of the HER2 gene amplification defined either by 
IHC or FISH. Previous reports demonstrate that EZH2 and Cyclin E/CDK2 both 
independently have been linked to the basal-like breast cancer phenotype, but no 
reported link between EZH2 and cyclin E/CDK2 has been reported in the 
literature. To begin to investigate the potential causal relationship between EZH2 
and cyclin E/CDK2 in sporadic triple-negative breast cancers, the clinical 
correlation between the expression levels of EZH2 and cyclin E/CDK2 was 
examined in breast cancer patient cohorts of triple-negative and non-triple-
negative groups.   
4.1.1. Correlation analysis of patients of triple negative group  
 A tissue microarray TNBC tissue cohort of 122 patients was stained via 
immunohistochemistry for EZH2 and cyclin E. Cyclin E expression level (59%) 
was slightly larger than the low expression population (41%) as previously 
reported. Interestingly EZH2 expression levels closely correlated with cyclin E 
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(p<0.0001) as illustrated in Table 4. EZH2 and cyclin E association is 
demonstrated by a representative IHC picture in Figure 4.  
4.1.2. Correlation analysis of patients of the non-triple negative group  
 As previously reported the non-triple negative patient cohort consisting of 
125 tissues demonstrated a population with less cyclin E expression (12%). 
EZH2 and cyclin E correlation was not observed with statistical significance in 
this cohort (P=0.53). The statistic result is shown in Table 4. 
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Table 4. Correlation between Cyclin E and EZH2. 
A. IHC staining result of triple-negative breast cancer tissues  
B. IHC staining result of non-triple negative breast cancer tissues 
 
Table 4. 
 
 
 
 
  
73 
Figure 4. Case representation demonstrating association between 
expression of EZH2 and Cyclin E in TNBC and non-TNBC 
A. Case representation of EZH2 and Cyclin E IHC in triple-negative breast 
cancer patient biopsy tissue 
B. Case representation of EZH2 and Cyclin E IHC in non-triple-negative breast 
cancer patient biopsy tissue 
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Figure 4. Case representation demonstrating association between 
expression of EZH2 and Cyclin E in TNBC and non-TNBC      
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4.2. Physical association between EZH2 and cyclin E/Cdk2 complex 
 Cyclin E has many characterized cellular functions involved in many 
central dogmas of cancer. Many of these functions are orchestrated through 
CDK2, the only defined compliment enzymatic partner of cyclin E. CDK2 
functions as a kinase capable of phosphorylating specific substrates causing 
changes in downstream signaling in normal and cancer cells. Knowing previously 
of the clinical correlation our group establish between cyclin E and EZH2, we 
pursued a potential regulatory mechanism of EZH2 being a phosphorylation 
substrate of CDK2. The physical association of EZH2 and CDK2 was examined 
both at a cellular level and in vitro. 
4.2.1. Ectopic Co-IP in co-transfected 293T cells 
 The physical association was determined by co-transfection of 3X-Myc-
EZH2 and HA-CDK2 in 293T cells at a 1:1 ratio followed by cell lysis and 
reciprocal Co-IP using either Myc or HA antibody. 
4.2.2. Endogenous Co-IP in candidate triple-negative breast cancer cell 
lines 
 To confirm that the binding observed in the 293T system also occurs 
endogenously specific to TNBC cells, a panel consisting of TNBC cell lines MDA-
MB 231, HS-578T, and BT-549 were immunoprecipitated using endogenous 
EZH2 antibody and later immunoblotted for CDK2. 
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4.2.3. Domain mapping of in vitro translated GST-EZH2 fragments and 
CDK2 
 In order to identify the EZH2 domain that CDK2 physically associates with 
HA-CDK2 was in vitro translated and labeled with S35 which was then incubated 
with GST-EZH2 fragments corresponding to domains I, II, and III (SET domain). 
EZH2 fragments corresponding to domains I, II, and III (SET domain) were pulled 
down using GST-sepharose beads and analyzed by SDS-PAGE and subsequent 
autoradiography. CDK2 was shown most significantly to associate with domain II 
of EZH2. 
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Figure 5. Cyclin E/CDK2 physically associates with EZH2 
A. Lysates from 293T transfected with 3X-Myc-EZH2WT and HA-CDK2 were 
immunoprecipitated using anti-MYC antibody and immunoblotted with anti-HA. 
Reciprocal experiments were done with corresponding antibodies  
B. Triple-negative breast cancer lines MDA-MB 231, BT549, and HS578T cells 
were subjected to immunoprecipitation with anti-EZH2 antibody and 
immunoblotted with anti-CDK2 antibody.  
C. HA-CDK2 was translated using in vitro translation assay, labeled with 35S and 
incubated with GST-EZH21-333, GST-EZH2334-610, or GST-EZH2611-746. GST pull 
down mapped the CDK2 interaction domain within EZH2 
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Figure 5. 
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4.3. Cyclin E/CDK2 enhances phosphorylation of EZH2 on T416 
 CDK2 phosphorylation substrates commonly contain the consensus 
phosphorylation motif of (S/T)PX(K/H/R), where phosphorylation is directed by 
proline to either the serine (S) or threonine (T) residue adjacent. Mapping of the 
EZH2 phosphorylation was performed in vitro and was identified to significantly 
occur within domain II of EZH2 on T416, an evolutionarily highly conserved 
consensus CDK2 phosphorylation site motif (described in detail in 4.3.2.). Moving 
forward a monoclonal mouse antibody was generated recognizing endogenous 
phospho-T416 EZH2 through collaboration with our sister laboratory’s antibody 
core facility, in Taiwan. 
4.3.1. Proline-directed threonine phosphorylation of EZH2 is enhanced by 
Cyclin/CDK2  
 Cyclin E overexpression was observed to increase proline-directed 
threonine phosphorylation under co-transfection with 3X-Myc-EZH2. Threonine 
phosphorylation was mitigated through additional transfection of dominant 
negative HA-CDK2 or drug treatment with CDK2 inhibitors II, III, or Roscovitine 
suggesting threonine phosphorylation can be promoted by CDK2 kinase activity. 
 
.     
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4.3.2. in vitro Cyclin E/CDK2 kinase mapping assay of GST-EZH2 
fragments 
 Knowing threonine phosphorylation can be enhanced via a CDK2 kinase-
activity-dependent manner we then mapped the phosphorylation residue using 
an in vitro cyclin E/CDK2 kinase mapping assay. To identify the exact threonine 
residue(s), first we generated and purified three GST-fused protein fragments of 
EZH2 were generated based on domain structure corresponding to domain I (1-
333), domain II (334-610), and domain III or SET domain (611-746). GST-EZH2 
fragments I, II and III were incubated with recombinant C-terminal 6X-His tag 
CDK2 and N-terminal GST tag Cyclin E in the presence of γP32-ATP in CDK2 
kinase buffer (NEB), analyzed by SDS-PAGE, and developed using 
autoradiography. Uniquely EZH2 domain II demonstrated the most significant 
phosphorylation signal which coincided with the presence in domain II of a highly 
evolutionarily conserved threonine-CDK2 phosphorylation consensus motif. Site-
directed point mutagenesis of T416A mitigated this phosphorylation signal, 
confirming T416 within domain II of EZH2 to be a CDK2 phosphorylation site. 
4.3.3. in vitro Cyclin E/CDK2 kinase assay of full length GST-EZH2  
 To confirm the in vitro mapping assay identification of the T416 
phosphorylation site,  GST-EZH2 full length protein was purified and incubated 
with recombinant C-terminal 6X-His tag CDK2 and N-terminal GST tag Cyclin E 
in the presence of γP32-ATP, analyzed by SDS-PAGE, and developed using 
autoradiography. Site-directed point mutagenesis of T416A again mitigated this 
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phosphorylation signal yielding confirmation that this phosphorylation site also 
occurs in a full length full-length intact EZH2-GST fusion protein. 
4.3.4. Generation of mouse polyclonal and monoclonal antibody targeting 
phospho-T416 EZH2 
 Mouse polyclonal antibody was generated by immunizing mice to a 
number of three to five times with a phospho-peptide (pT416) flanked by bilateral 
extension to the N-and C-terminal representative of the region encompassing 
T416, ANSRCQ-pT416-PIKMK-MAP. Serums were screened for using a pT416-
peptide based ELISA and positive serums were further verified by dot blot using 
competitive peptide titrations. For in vivo verification, co-transfection assays used 
in 4.3.1 were performed, using the phospho-mitigated EZH2 mutant T416A as a 
negative control.  Moue monoclonal antibody (mAb) was screened for in several 
hybridoma cell lines using the ELISA method mentioned above. Confirmation of 
the specificity of the antibody for immunoblotting and IHC was also determined in 
a similar manner. 
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Figure 6. Identification and verification of EZH2 phosphorylation site by 
Cyclin E/CDK2  
A. Lysates from 293T transfected with Cyclin E, Myc-EZH2WTwere 
immunoprecipitated using anti-MYC antibody and immunoblotted with anti-Myc, 
p-NPM, NPM, or anti-phospho-Threonine/proline antibodies. 293T cells were 
treated with and treated with CDK2 inhibitor I, II, or Roscovitine. 
B. Schematic of GST-EZH2 fragment domain structure with hi-lite of the 
evolutionarily conserved CDK2 consensus phosphorylation motif. 
C. Mapping of T416 EZH2 phosphorylation to GST-EZH2 protein fragment 
domain II using in vitro kinase assay  
D. Identification and confirmation of T416 phosphorylation in full-length GST-
EZH2 protein. 
E. Lysates from 293T transfected with Cyclin E, Myc-EZH2WT Myc-EZH2T416A 
were immunoprecipitated using anti-MYC antibody and immunoblotted with anti-
Myc, p-NPM, NPM, or anti-phospho-T416 EZH2 antibodies after 
immunoprecipitated using anti-MYC antibody. 293T cells were treated with and 
treated with CDK2 inhibitor I, II, or Roscovitine. 
F. Dot blots characterization of phospho-T416 EZH2 antibody under phospho-
peptide competition assay.  
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Figure 6.  
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4.4 T416 phosphorylation increases TNBC patient mortality 
 EZH2 phosphorylation on T416 serving as potential biomarker for 
BLBC/TNBC patients may function as a predictive tool to determine which 
BLBC/TNBC patients are at benefit for CDK2 or EZH2 inhibitor based therapies. 
Very few predictive tools are available for BLBC patients and T416 
phosphorylation therefore could serve as one of the first in kind predictive 
therapy markers. Further validation of such mentioned CDK2 and EZH2 
therapies are shown later on in the BLBC/TNBC cell line tumor sphere killing 
assay. 
4.4.1 Survival analysis of TNBC patients exhibiting high levels of T416 
phosphorylation 
 Generation of the monoclonal EZH2 T416 phosphorylation antibody 
permitted further investigation into the TNBC cohorts. Survival data was available 
for most of the 125 TNBC tissue samples originally used to establish the clinical 
correlation between Cyclin E and EZH2 co-expression. Out of the 125 tissue 
samples on the TNBC TMA 100 were available for staining and had 
corresponding survival data available. Using the mouse mAb for phospho-T416-
EZH2 (pT416) we determined TNBC patients with high T416 phosphorylation 
had shorter survival time compared to those TNBC patients with low pT416. The 
specificity of the pT416-mAB was determined using a native and phospho-
peptide competition staining control. 
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4.4.2 Survival analysis of non-TNBC patients exhibiting high levels of T416 
phosphorylation 
 Survival data was available for a more limited number of the 125 non-
TNBC tissue samples originally used to establish the clinical correlation between 
cyclin E and EZH2 co-expression. Out of the 125 tissue samples on the TNBC 
TMA, 79 were available for staining and had corresponding survival data 
available. Using the mAb for phospho-T416-EZH2 (pT416-EZH2) we determined 
there was not a correlation between pT416 levels and survival in non-TNBC 
patients. 
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Figure 7. Correlation between pT416 levels and patient survival in triple-
negative and non-triple negative breast cancer 
A. Case representation of high EZH2-T416 phosphorylation (pT416) and low 
EZH2-T416 phosphorylation 
B. Survival analysis of patients with high and low pT416 in triple-negative breast. 
C. Survival analysis of patients with high and low pT416 in non-triple-negative 
breast. 
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Figure 7. 
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4.5 Cell cycle dependency of T416 phosphorylation 
 EZH2 is a cell cycle regulated protein transcriptionally controlled by the 
Rb/E2F transcriptional pathway at the beginning of G1/S phase of the cell cycle. 
CDKs are well known for controlling cell cycle checkpoints. Recently EZH2 has 
been shown to be phosphorylated by both CDK1/CDK2 on T345 and 
phosphorylated by specifically by CDK1 on T487. Functionally the T345 residue 
was capable of changing lncRNA binding with EZH2 while T487 phosphorylation 
disrupted the PRC2 complex association to inhibit mesenchymal stem cell 
differentiation. Both phosphorylation residues were shown to be cell cycle-
dependent when observed under double thymidine or nocodazole 
synchronization conditions. 
4.5.1 T416 phosphorylation is enhanced in G1/S stage of the cell cycle 
 The cell cycle dependency of the EZH2 T416 phosphorylation was 
determined by double thymidine block to synchronize cells in the G1/S phase to 
a level of %80 synchronization. Cells were then released from double thymidine 
blockade and the custom pT416 mAB was used to monitored T416 
phosphorylation as cells progressed from G1/S to the G2/M stage of the cell 
cycle. In Hela cells, a canonical cell synchronization model cell line, and in the 
BLBC cell line, MDA-MB-231, T416 phosphorylation peaked at G1/S when the 
cyclin E level also was the highest. As cyclin E levels decreased in both cell lines 
the T416 phosphorylation also decreased and was diminished upon entry into 
G2/M. This shows T416 phosphorylation is enhanced through cyclin E 
expression during the cell cycle and can be sustained by cyclin A after G1/S to a 
  
97 
lesser extent until CDK2 activity is depleted upon entering M-phase. Upon 
entering M-phase it is predicted that the T416 phosphorylation is reduced to a 
greater extent when compared to G2/M, if not abolished completely. 
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Figure 8. Cell cycle dependency of EZH2 T416 phosphorylation 
A. Hela cells synchronized and released using double-thymidine block and 
monitored from 0, 30min (“) to 14hrs (‘) after removal of thymidine block 
B. MDA-MB 231 cells synchronized and released using double-thymidine block 
and monitored from 0, 30min (“) to 14hrs (‘) after removal of thymidine block 
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Figure 8.   
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4.6 EZH2 T416 phosphorylation enahnces measures of breast cancer 
agressiveness similar to BLBC 
 EZH2 enhances many of the Hanahan and Weinberg described cancer 
cell dogmas. In order to determine if EZH2 T416 phosphorylation can increase 
breast cancer tumorigenesis similar to BLBC/TNBC we tested cellular functions 
paralleled by known oncogenic functions of EZH2 in promoting breast cancer 
aggressiveness similar if not overlapping with the aggressive traits intrinsic to 
BLBC/TNBC. 
4.6.1 EZH2 T416 phosphorylation does not enhance 2-D growth of breast 
cancer 
 BLBC/TNBC breast cancer often has a higher proliferative rate as 
determined by ki67 antigen IHC staining in patient biopsies. Other growth assays 
have also been used to determine increases in breast cancer cell proliferation 
such MTT, Brdu, or CFU. In order to determine if T416 phosphorylation can 
enhance BLBC/TNBC cell proliferation MDA-MB 231-vector, MDA-MB 231-
EZH2-WT, MDA-MB 231-EZH2-T416A and MDA-MB 231-EZH2-T416D stable 
clones were generated via lentiviral infection expressing the respective EZH2 
point mutation variants. Proliferation rates amongst the MDA-MB 231 cells with 
EZH2 overexpression did not have a change in cell proliferation when measured 
by MTT or CFU assay suggestion T416 phosphorylation does not increase 
growth of BLBC/TNBC cells under 2-D culture conditions. CDK2 knockdown 
(MDA-MB 231 shCDK2) and EZH2 (MDA-MB 231 shEZH2) knockdown by 
shRNA lentiviral infection demonstrated reduction in cell growth measured by 
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both CFU and MTT assay confirming altering EZH2 or CDK2 functional levels 
through reducing protein levels was able to change growth of MDA-MB 231 cells 
in a 2-D culture environment.  Because breast cancer cells often require a 3-D 
support to properly reflect their normal growth behavior in tissue culture settings 
we treated the 2-D growth result as an artifact of culture conditions and looked to 
confirm the result under 3-D growth conditions using the above mentioned cell 
lines cultured in a soft-agar anchorage-independent growth setting. 
4.6.2 EZH2 T416 phosphorylation enahnces breast cancer cell growth in a  
3-D dependent manner 
 As described MDA-MB 231-vector, MDA-MB 231-EZH2-WT, MDA-MB 
231-EZH2-T416A, and MDA-MB 231-EZH2-T416D stable clones generated via 
lentiviral infection were cultured under 3D-growth conditions or formally known as 
soft-agar anchorage-independent growth conditions. Differences in growth 
characteristics were more readily observed. Under soft-agar growth conditions 
T416A expressing cells exhibited reduced colony formation capacity compared to 
WT expressing cells. Conversely, T416D expression increased the colony 
formation capacity of MDA-MB 231 cells compared to WT expressing cells. This 
data suggests that the colony formation capacity of MDA-MB 231 cells can be 
increased through expression of the T416 EZH2 phosphorylation phospho-
mimetic point mutant expression, T416D, and reduced when the cells express 
the T416-phospho null EZH2 point mutant. Similarly to 2-D culture conditions 
EZH2 or CDK2 knockdown also reduced cell growth under soft agar conditions 
Overall this suggests modulation of T416 phosphorylation represented by alanine 
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(A) or aspartic acid (D) point mutation can reduce or enhance BLBC/TNBC cell 
growth in 3-D growth culture environment, respectively. 
4.6.3 EZH2 T416 phosphorylation enhances breast cancer migration and 
invasion 
 EZH2 overexpression and phosphorylation by CDK1 on T487 have been 
shown influence breast cancer cell migration and invasion. Invasion and 
migration increase when EZH2 expression level is elevated in many normal and 
cancer cell types, including BLBC. We examined the stable clones mentioned in 
4.6.1 that stably express EZH2-(WT, A, D) in the modulatory context of T416 
phosphorylation previously mentioned.  Similar to the growth advantage gained 
based on the represenative phosphorylation mimics by cells expressing EZH2 D-
form form compared to EZH2 WT, these cells were also observed to have an 
increased ability in their migration through boden chamber pores and invasion 
ability through growth factor-reduced matrigel filters. EZH2 A-form expressing 
cell migration and invasion ability were mitigated compared to EZH2 WT 
expressing cells. Similarly to 2-D culture conditions EZH2 or CDK2 knockdown 
also reduced cell migration and invasion. This data suggests that EZH2 T416 
phosphoryaltion may be able to provide BLBC cells with an ability to home to 
growth factor signaling and cross tissue barriers mimicing in an in vitro manner, 
metasastic cellular programs. 
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Figure 9. T416 phosphorylation enhances 3-D dependent growth and 
migration/invasion  
A. Overexpression of vector control (V), and 3XMyc-EZH2-WT(WT), EZH2-
T416A (A), EZH2-T416D (D) . Lower panel is lentiviral luciferase knockdown 
control (shLuc), EZH2 knockdown (shEZH2), and CDK2 knockdown (shCDK2). 
Both upper and lower panel are in MDA-MB 231 breast cancer cells. 
B, C. Colony formation assay using lentiviral V and EZH2 -WT, A, D-forms 
shLuc, shEZH2 and shCDK2 MDA-MB 231 cells. 
D, E. MTT assay using lentiviral V and EZH2 -WT, A, D-forms of shLuc, shEZH2 
and shCDK2 MDA-MB 231 cells. 
F, G. Soft-agar assay using lentiviral V and EZH2 -WT, A, D-forms shLuc, 
shEZH2 and shCDK2 MDA-MB 231 cells.  
H. Migration assay using lentiviral V and EZH2 -WT, A, D-forms of MDA-MB 231 
expression cells 
I. Invasion assay using lentiviral V and EZH2 -WT, A, D-forms of MDA-MB 231 
expression cells 
J. Migration assay using lentiviral shLuc, shEZH2 and shCDK2 MDA-MB 231 
cells. 
K. Invasion assay using lentiviral shLuc, shEZH2 and shCDK2 MDA-MB 231 
cells. 
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Figure 9. 
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4.6.4 EZH2 T416 phosphorylation enhances breast cancer tumor sphere 
formation 
 Many types of cancer stem and progenitor cells, including breast cancer 
cells have demonstrated EZH2 to be fundamental in the biology and in promoting 
the expansion of upper lineage cell populations. How EZH2 regulates each of 
these respective tumor initiating cells populations has been studied in many 
laboratory setting, but the signaling transduction mechanisms that regulate EZH2 
in these cell populations or how these signal transduction events regulate EZH2 
to generate or maintain these cell populations is yet to be elucidated. Knowing 
that EZH2 T416 phosphorylation was able to enhance colony formation in 3-D 
growth dependent manner based on T416D point mutation we asked if EZH2 
T416 phospho mimetic (D-form) or phosphor-null (A-form) EZH2 variants can 
influence tumor sphere formation when the stable lines mentioned in 4.6.1 are 
seeded 10,000 cells/well in a non-adherent culture dish with the cells cultured in 
Mammocult media (Stem Cell Tech. Inc). After 7-10 days in the above culture 
media it was observed that tumor spheres formed by EZH2-WT expressing cells 
compared to those formed by A-form expressing cells had a 2-fold reduction in 
the number of tumor spheres formed. Moreover, the D-form expressing cells 
increased their number of spheres formed compared to EZH2-WT expressing 
cells by 2-fold, demonstrating EZH2 T416 phosphorylation can promote the 
formation of BLBC/TNBC tumor spheres.  Sphere formation was confirmed to be 
both CDK2 and EZH2 dependent as shCDK2 cells had 9-fold reduction in tumor 
sphere number formation and shEZH2 cells had a 22-fold reduction in tumor 
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sphere formation, respectively. To determine if the elevated sphere formation 
was due to increased stem cell or progenitor cell population expansion, the 
respective cell populations were stained for changes in CD44/CD49f positive and 
CD24 /EPCAM negative cell populations. Cells were also stained using Aldefluor 
assay (Stem Cell Tech. Inc) to look at ALDH1 activity. After staining no apparent 
differences were seen in cell surface marker expression or ALDH1 activity 
between the stable lines expressing EZH2-WT, A-form, or D-form (data not 
shown),  suggesting the increase in tumor sphere formation number is not due to 
an expansion in the breast cancer stem cell population. However this may be 
suggestive of the increase in sphere number being alternatively derived from a 
tumorigenic breast cancer progenitor cell population, but we were unable to 
identify the population by representative cell surface marker characterization. 
 
4.6.5 EZH2 T416 phosphorylation enhances xenograft tumor growth 
 The observation that EZH2 T416 phosphoryaltion leading to increased 3-
D growth an invasion potential asked the question whether or not EZH2 T416 
phosphoryaltion has the ability promote in vivo tumor growth. The stable lines 
mentioned in 4.6.1, including EZH2 and CDK2 knockdown cell lines, were 
therefore evaluated in their ability to produce tumors in a xenograft mouse model. 
Each respective cell line was injected into a nude female mouse mammary fat 
pad using 2.0X106 cells per injection. It was determined that EZH2 T416 
phosphorylation increases in vivo tumorigenecity as the EZH2 A-form cell line 
tumor growth was mitigated and the EZH2 D-form tumor growth was enhanced 
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compared to EZH2-WT expressing cells. CDK2 and EZH2 knockdown cells both 
mitigated tumor growth. Taken together this demonstrates EZH2 T416 
phosphoryaltion is candidate residue capable of enahncing tumor growth when 
T416 phosphorylation is mimicked by T416D point mutation and that T416 
phosphorylation thus serves as a potential target for phamacological inhibition 
that can reduce BLBC tumor growth. 
 
4.6.6 CDK2 inhibitor or EZH2 inhibitor reduces tumor sphere formation 
number 
 Both aberrant or hyperactivation of CDKs (i.e. CDK2) and EZH2 (through 
PRC2 function)  has been shown to favor tumor development via expansion of 
cancer stem or progenitor cells through unscheduled cell division in either of 
these upper lineage breast cancer cell populations. Therefore inhibition of CDK2 
or EZH2 may be a suitable intervention and drugable strategy for treating BLBC. 
Based on acquired knowledge that EZH2 T416 phosphorylation can enhance 
tumor sphere growth we developed a tumor sphere drug killing assay using 
BLBC-derived spheres as tissue culture test spheres. The rationale is to develop 
a target therapy to target progenitor cells or stem cells from the tumor. Tumor 
stem cell or progenitor cells are possessive of plasticity elements capable of 
generating or regenerating tumor biology heterogenic hierarchy components and 
are the cells resistant to conventional and known BLBC/TNBC proposed 
therapies. Therefore, if candidate therapy regimens show positive results in the 
sphere assay derived from BLBC/TNBC derived cell lines it may provide a 
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through-put design to test and optimize CDK or EZH2 based therapy treatment 
plans. Further validation can be achieved in vivo after initial sphere assay 
screening. 
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Figure 10. T416 phosphorylation enhances tumor sphere formation number 
and xenograft tumor growth and sphere number can be inhibited by 
SNS032 or GSK126 
A. Tumor sphere assay using Mammocult media with V and EZH2 -WT, A, D-
forms of MDA-MB 231 expression cells 
B. Tumor sphere assay using Mammocult media with shLuc, shEZH2 and 
shCDK2 MDA-MB 231 cells. 
C. Xenograft tumor growth of with V and EZH2 -WT, A, D-forms of MDA-MB 231 
expression cells 
D. Xenograft tumor growth of with shLuc, shEZH2 and shCDK2 MDA-MB 231 
cells. 
E.  Tumor sphere inhibition by CDK2 inhibitor treatment with SNS032 or EZH2 
inhibitor treatment with GSK126 
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Figure 10. 
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CHAPTER 5. DISCUSSION 
 The cellular architecture of the mammary tissue provides the mammary 
gland a dynamic system for tissue homeostasis. The structured composition 
makes the tumorigenic events occurring at the different layers in the hierarchical 
tissue environment of the breast develop tumors with a highly heterogenic 
nature. Mammary tumors may arise in different layers of the breast tissue, from 
the basal-layer epithelium enriched in populations of undifferentiated cell types or 
the luminal layers of more differentiated cell lineages, including terminally 
differentiated cell types. Tumors arising from the basal-layer are thought to be 
the origin of BLBC. These basal-layer derived tumors are hormone receptor-
lineage unrestricted, meaning they do not express estrogen-alpha or 
progesterone receptors and are often similar to the gene expression profiled 
tumors of BLBC that were identified in the original subtype classification or via a 
PAM50 test. Often tumors of the basal origin are also negative for HER2 
expression. In addition the tumors derived from this area of breast tissue are 
often enriched in upper lineage breast cancer stem or progenitor cells, a 
characteristic also observed in many BLBC/TNBCs. The expression of estrogen-
alpha, progesterone, and HER2 receptors is the marker standard that provides a 
mammary oncologist with a classification scheme and a mode of treatment 
planning for the breast cancer subtype treatment based on the ER-
alpha/PgR/HER2 expression. ER-alpha/PgR/HER2 markers are the most 
frequently targeted by current therapies and without their expression, such as 
with the case with BLBC, targeted therapies are very limited. Furthermore, BLBC 
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demonstrates high resistance levels to conventional chemotherapies making 
BLBC only treatable by putative care. Understanding the underlying principles 
that governs BLBC essential biology and therapy resistance will help in the 
development of new targeted therapies for BLBC/TNBC. Identification of new 
biomarkers and signaling pathways promise better care for BLBC/TNBC patients. 
New biomarkers may be regulated by essential signal transduction pathways 
previously identified in BLBC/TNBC. The biomarkers may give a read-out of the 
activity of such previously studied, but untreated pathways. In order to target 
these pathways we need to understand the level of crosstalk and how the 
pathway interactions promote the aggressive nature of BLBC/TNBC through 
regulation of the new biomarkers. 
 BRCA1 breast cancer is used as a BLBC/TNBC model because to date it 
is the most clinically relevant representation. Patients that have inherited BRCA1 
mutations almost all develop tumors BLBC/TNBC characteristics, including a 
tumors with poorly differentiated cellular morphology and enrichment in cancer 
stem or progenitor cell populations. EZH2 overexpression has been shown to 
decrease the expression of BRCA1 protein and moreover cell lines derived from 
tumors resected from BRCA1 mutation carriers show a dependency on EZH2 
expression. The EZH2 overexpression experiments show that ectopic addition of 
EZH2 also increases the size of the breast cancer stem cell niche. It is known 
that EZH2 overexpressing tumors and BRCA1 deficient tumors both developing 
undifferentiated breast cancers that both tumor types share similar gene 
signatures. The above mentioned evidence is suggestive of EZH2 playing a role 
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in modulating the biology of BLBC/TNBC in a manner either dependent or 
independent of EZH2 down-regulating BRCA1. Further study is needed to 
determine if EZH2 overexpression BLBC/TNBC tumors require BRCA1 loss to 
elicit their mode of tumorigenic action and phenotype development. It is known 
that EZH2 by one of two ways can cause the development of BLBC/TNBC or 
undifferentiated carcinomas (option 1) by maintaining cells in a non-differentiated 
state, including a stem cell state or (option 2) through a process of de-
differentiation, most likely through EZH2-PRC2 dependent function; one route 
being through epigenetic repression or down-regulation of  BRCA1. Both 
mechanisms are similar to the breast cancer stem or progenitor cell hypothesis, 
which as previously mentioned in 2011 Chang et al. demonstrated EZH2 can 
expand the breast tumor initiating cell or breast cancer stem cell populations. 
Whether the study by Chang et al was through a process of option 1 or option 2 
is yet to be determined. None the less taken together this exhibits how EZH2 
provides an important thread for the biology and architecture of BLBC/TNBC 
tumors, possibly through regulating breast cancer stem cell or progenitor cell 
populations. 
 Relatedly, cyclin E/CDK2 has been demonstrated to be involved in studies 
demonstrating involvement in the development and progression of BLBC/TNBC. 
For example high cyclin E expression is observed in BRCA1 mutation carriers 
and the high expression cyclin E negatively correlates with poor survival of the 
BRCA1 mutation carrier patients. Because CDK2 activity is directly reflected by 
cyclin E expression owing to the cyclin E being the activating adaptor protein of 
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CDK2, this demonstrates that the elevated cyclin E level is consequently 
increasing CDK2 activity therefore CDK2 kinase function likely plays a role in the 
development of these BLBC/TNBC tumors. This is further supported by not only 
high expression of cyclin E protein being observed in BRCA1-derived BLBCs, but 
also through the observation of the loss of the CDK2 inhibitor protein, p27, in 
these BRCA1-derived tumors resulting in elevated CDK2 activity. The elevation 
in CDK2 activity being important for BLBC/TNBC can most directly be observed 
in a constitutively active CDK2 fusion protein being capable of promoting the 
development of breast tumors with a basal-like component in an MMTV mouse 
model. Overall this data suggests that CDK2 activity and expression can promote 
the development of tumors with BLBC/TNBC phenotypic traits.    
EZH2 and its PRC2 component SUZ12 have been shown to be 
transcriptionally regulated by Rb/E2F during the G1/S phase of the cell cycle. 
Both EZH2 and SUZ12 proteins exhibit peak expression during the G1/S 
transition checkpoint. At this same stage of the cell cycle CDK2 activity also 
peaks with continuous activity until the G2/M transition being elicited through 
activation by A-type cyclins. EZH2 has been shown to bind to and be 
phosphorylated by CDK1/CDK2 in a cell cycle dependent manner. This suggests 
that PRC2 activity and thus EZH2 activity may be enhanced through aberrant 
activation or deregulation of the cell cycle, specifically through CDK2 activity and 
CDK2 phosphorylation of EZH2 during the cell cycle. As mentioned aberrant 
PRC2 activity is synonymous with maintaining undifferentiated cell states with 
BLBC/TNBC gene signatures, an increased size in the niche pool of cancer stem 
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or progenitor cells and coincidently aggressive tumor traits representative of 
BLBC/TNBC. Understanding the underlying signaling events that generate the 
development and maintenance of the biology of BLBC through the deregulation 
of the cell cycle that leads to a hyperactivated PRC2, specifically the site of 
interest in this study, EZH2 T416 phosphorylation. Understanding EZH2 T416 
phosphorylation and how it governs BLBC/TNBC biology will provide insight into 
the development of rationalized targeted therapies for mammary oncologist to 
make available for BLBC/TNBC patient care options. 
5.1. Cell cycle regulatory role of the PRC2 through EZH2 T416 
phosphorylation  
 It can be said the cell cycle stage where CDK2 activity is the highest at 
G1/S via E-type cyclins, is where EZH2 expression level peaks during the cell 
cycle. CDK2 activation by A-type cyclins sustains CDK2 activity throughout the 
cell cycle until G2/M, the point where EZH2 expression level decreases therefore 
from G1/S to G2/M EZH2 possesses the potential for being modulated by CDK2 
T416 phosphorylation. Phosphorylation of EZH2 on T416 by CDK2 suggests a 
mechanism that could contribute to deregulated histone modification by the 
PRC2 gene silencing mechanisms in a cell cycle dependent manner in 
BLBC/TNBC. Elucidating how the epigenetic mosaic is altered in BLBC/TNBC 
may display further targets unveiled through CDK phosphorylation of EZH2. It is 
because cyclin-dependent kinases, CDK1 and CDK2 have been shown to control 
EZH2 function and both EZH2 and cyclin E /CDK2 expression negatively 
correlate with TNBC patient survival and progression, that an interesting question 
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was raised as to whether there is a functional relationship between cyclin 
E/CDK2 and EZH2 in the relation to the generation and maintenance of TNBC. 
Cohorts of 122 primary TN and 125 non-TN breast tumor tissues stained for 
cyclin E and EZH2 revealed that a high cyclin E expression level closely 
correlates with elevated EZH2 expression in the TNBC (p<0.0001). When the 
non-TNBC cohort, did not show correlation between cyclin E and EZH2 
expression (p=0.53) it suggested a possible relationship between Cyclin E and 
EZH2 protein expression in important for the biology of BLBC/TNBC. Recently 
several publications have shown that CDK2, the only known enzymatic partner of 
cyclin E, can physically associate with EZH2. We confirmed this interaction in 
BLBC/TNBC breast cancer cell lines via co-immunoprecipitation. CDK2 
interaction domain of EZH2 was mapped using in vitro translated S35 labeled HA-
CDK2 co-incubated with GST-amino terminus fused EZH2 fragments 
representative of either EZH2 function domain I (amino acid residues 1-333), 
domain II (amino acid residues 334-610), or domain III, the SET domain (amino 
acid residues 611-746) and revealed that CDK2 predominantly associated with 
domain II of EZH2. An in vitro protein kinase assay performed via incubation of 
cyclinE-CDK2 complex with each of the GST-EZH2 fusion proteins showed 
domain II was the only domain phosphorylated by cyclin E/CDK2.  Interestingly, 
domain II contains an evolutionary conserved CDK2 phosphorylation motif 
(K(R)S(T)PXK(R), where X is any residue. T416A mutagenesis mitigated CDK2 
phosphorylation in vitro within domain II and in ectopically expressed full-length 
EZH2-T416A when compared to EZH2-WT in the presence of overexpressed 
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cyclin E suggesting T416 is likely to be the major site phosphorylated by CDK2. 
The in vitro protein kinase assay performed using GST-EZH2 domains was 
confirmed via incubation of cyclinE-CDK2 complex with GST-EZH2 full-length 
fusion proteins to demonstrate the mapping of the T416 phosphorylation site was 
not an artifact of protein truncation.  The T416A mutation has been reported to 
reduce EZH2 phosphorylation in vitro, but the function of EZH2 T416 
phosphorylation (pT416) has yet to be elucidated. To investigate whether pT416 
exists in vivo we generated a mouse monoclonal antibody against the pT416 
containing peptide which was characterized using a peptide dot blot assay to 
determine its specificity and sensitivity. Ectopic expression of cyclin E strongly 
enhanced the pT416, while phosphorylation of EZH2-T416A was virtually 
undetectable. Consistently, pT416 was not detectable in cells expressing DN-
CDK2D146N or cells treated with three different CDK2 specific inhibitors, indicating 
CDK2 is the kinase that phosphorylates T416 on EZH2. 
 To study the cell cycle dependency of the T416 EZH2 phosphorylation we 
intended to establish a cell culture system of synchronized cell populations and 
monitor pT416 as cells were released from their synchronization block and 
progressed through the cell cycle in a uniform manner. Hela cells, a canonical 
cell line model for cell cycle synchronization, were used in addition to the 
candidate TNBC cell line MDA-MB 231 cells. Cells were synchronized using 
double thymidine-block to achieve %80 cell cycle synchronization in G1/S phase. 
After synchronization cells were released from their cell cycle block and let to 
progress through the cell cycle in a synchronized manner. Both Hela cells and 
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MDA-MB 231 cells showed peak T416 phosphorylation of EZH2 during G1/S 
paralleling the peak expression of cyclin E. As expression of cyclin E decreased 
progressing toward the entry of G2/M, the pT416 also decreased. Notably EZH2 
total protein level was also being reduced as the pT416 decreased. Half-life 
experiments with EZH2 and cyclin E ectopic co-expression in 293T cells 
determined T416 phosphorylation did not enhance EZH2 protein stability. Hela 
and MDA-MB 231 cells were also synchronized in either G1/S or G2/M using 
double-thymidine block and nocodazole block, respectively. Cells synchronized 
in G1/S demonstrated increased pT416 compared to unsynchronized cells. An 
increase in pT416 was not observed in cell synchronized with nocodazole. Taken 
together, these data indicate CDK2 binds to and phosphorylates EZH2 on T416 
and pT416 is regulated in a cell cycle dependent manner and demonstrate the 
potential for T416 phosphorylation by EZH2 to control PRC2 gene silencing when 
compared to other precedent EZH2 phosphorylation events that demonstrated 
similar mechanisms after phosphorylation 
5.2. Clinical significance and tumorigenic functions of EZH2 T416 
phosphorylation  
 To investigate the clinical significance of EZH2 T416 phosphorylation the 
monoclonal antibody for EZH2 T416 phosphorylation was used to 
immunohistochemical stain cohorts of 122 primary TN and 125 non-TN breast 
tumor tissues. Validation of the phospho-T416 EZH2 (pT416-EZH2) antibody 
was performed using peptide competition assays. Examination of the TNBC 
cohort demonstrated that when T416 phosphorylation of EZH2 was elevated 
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there was a decreasing trend for patient survival with statistical significance 
(p=0.049). The non-TNBC cohort did not exhibit a distinguishable survival trend 
(p>0.05) Taken together this suggest T416 phosphorylation of EZH2 can serve 
as prognostic biomarker to predict TNBC survival. This phosphorylation serving 
as a biomarker can be directly linked with cyclin E expression and CDK2 activity 
by establishing the co-expression significance of either cyclin E or CDK2/p-CDK2 
with EZH2 T416 phosphorylation. In this manner the clinical significance of T416 
phosphorylation can be demonstrated to be potentially dependent upon CDK2 
activity and yield rationale for the development of a CDK2 inhibitor based therapy 
for TNBC patients exhibiting the EZH2 T416 phosphorylation biomarker. 
 Moreover, this TNBC cohort staining asks whether EZH2 T416 
phosphorylation can predict TNBC metastasis potential or predict other functions 
of TNBC related to known EZH2 oncogenic traits based on the modulation of 
T416 phosphorylation. Biomarkers to predict and diagnose TNBC behavior are 
not readily available. Further understanding of the TNBC biology that is driven by 
EZH2 T416 phosphorylation thus will allow for a better understanding of how 
tumors are developing under this post-translational modification of EZH2. The 
type of mammary tumors developed under T416 phosphorylation will allow 
oncologist to combine CDK2 inhibitor based regimens with other conventional 
and existing therapies based on the related behavior predicted by EZH2 T416 
phosphorylation. To test whether pT416-EZH2 induced a BLBC with enhanced 
tumorigenesis, we examined TNBC functional hallmarks that overlap with known 
EZH2 function including (1) increased cell proliferation, (2) anchorage-
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independent growth, and (3) migration/invasion in MDA-MB 231-vector, MDA-MB 
231-EZH2-WT, MDA-MB 231-EZH2-T416A, and MDA-MB 231-EZH2-T416D 
stable clones generated via lentiviral infection. As reported EZH2 overexpression 
exhibited a change in cell proliferation based on colony formation assay results 
between the vector and EZH2 (WT, A, or D) cell lines but proliferation of MDA-
MB 231 stable cell lines did not exhibit any change in proliferation capacity 
amongst the T416 phosphorylation wild-type or modulated cell lines MDA-MB 
231-EZH2-WT, MDA-MB 231-EZH2-T416A, and MDA-MB 231-EZH2-T416D. 
Similar results were observed using MTT proliferation assay for the same cell 
lines. Reduced growth was observed MDA-MB 231-shCDK2 and MDA-MB 231-
shEZH2 cells with knockdown of CDK2 or EZH2, respectively. Notably, a change 
in the growth of cells in anchorage independent fashion was observed when 
MDA-MB 231-EZH2-WT, MDA-MB 231-EZH2-T416A, and MDA-MB 231-EZH2-
T416D cells were grown under soft-agar growth conditions or in 3D-growth 
conditions. Under these 3D-gorwth culture conditions MDA-MB 231-EZH2-T416A 
demonstrated reduced cell growth while the T416 phospho-mimetic cell line, 
MDA-MB 231-EZH2-T416D, demonstrated an increase in cell proliferation 
compared to MDA-MB 231-EZH2-WT. Similarly, MDA-MB 231-EZH2-T416A 
demonstrated reduced migration and invasion ability while the T416 phospho-
mimetic cell line, MDA-MB 231-EZH2-T416D, demonstrated an increase in 
migration and invasion ability compared to MDA-MB 231-EZH2-WT. Tumor 
sphere formation assay demonstrated that in addition to the EZH2-T416D 
phospho-mimetic form of EZH2 inducing and the EZH2-T416A phospho-null 
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mimetic mitigating  enhanced 3D-growth culture-dependent cell proliferation, 
migration, and invasion that T416 phosphorylation also promotes an increase 
breast cancer cell capacity to form increased tumor sphere numbers. MDA-MB 
231-shCDK2 and MDA-MB 231-shEZH2 cells showed reduction in the 
aforementioned abilities of 3D-dependent culture growth, migration/invasion, and 
increased tumor sphere formation number demonstrating each function is 
dependent also upon specifically CDK2 or EZH2. Of interest there was not a 
notable increase in cell populations representative of breast cancer stem cells as 
seen by there existing no change in CD44, CD24, CD49F, EpCAM expressing 
populations or by cells displaying increased ALDH1 activity. This suggests that 
the increase in sphere formation was not due to enrichment of breast cancer 
stem cells, but instead indicative of a unidentified breast cancer progenitor cell 
population. Taken together this demonstrates that in endogenous cell lines EZH2 
T416 phosphorylation can enhance breast cancer tumorigenecity in a manner 
indicative of traits observed to be exacerbated in BLBC. To establish in vivo 
relevance of EZH2 T416 phosphorylation orthotopic xenograft tumor models of 
MDA-MB 231-vector, MDA-MB 231-EZH2-WT, MDA-MB 23-EZH2-T416A, and 
MDA-MB 231-EZH2-T416D were generated via mammary fat pad injection. The 
orthotopic tumor models demonstrated reduced ability of MDA-MB 231-EZH2-
T416A cells to induce tumor growth in vivo compared to MDA-MB 231-EZH2-WT. 
MDA-MB 231-EZH2-T416D cells were capable of increased tumor growth more 
MDA-MB 231-EZH2-WT (Figure 4E). MDA-MB 231-shLuc, MDA-MB 231-EZH2-
shCDK2, and MDA-MB 231-EZH2-shEZH2 cells were also used as a control for 
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the orthotopic xenograft model. Knockdown of both CDK2 (MDA-MB 231- 
shCDK2) and EZH2 (MDA-MB 231-shEZH2) demonstrated reduction of in vivo 
tumor growth similar to MDA-MB 23-EZH2-T416A cells. As a result this data 
suggests that both in endogenous culture system and in vivo mouse models, that 
EZH2 T416 phosphorylation can present breast cancer cells with the ability to 
increase their tumorigenecity through a predicted PRC2 mode of action. Further 
ChIP-Sequencing studies need to be performed to specifically see how T416 
phosphorylation alters breast cancer gene expression profiles. 
5.3. Utilizing CDK2 inhibition to reduce tumor sphere growth in BLBC 
 During the past two decades an ongoing list of publications has 
exemplified the common occurrence in cancer cells of cell cycle deregulation. 
Many tumors acquire mutation hits that invoke constitutive mitogenic signaling 
combined or the inability to process anti-mitogenic signaling, both resulting in 
unchecked cell proliferation. In a contributing manner most tumors develop a 
level of genomic instability that can enhance the number and frequency of 
mutations as well as chromosomal instability, an alteration in the tumor cell’s 
chromosomal number. Compounding of these cellular abnormalities creates a 
slippery slope increasing the susceptibility to the accrual of additional genetic 
shifts that lead to the development of tumor progression and more aggressive 
phenotypes through infinite genetic variation.  These basic cell cycle defects of 
unchecked proliferation, genomic instability, and chromosomal instability are 
mediated both directly and indirectly by aberrant deregulation of CDKs. One of 
the underlying hallmarks of BLBC is genomic stability. The increased mutational 
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rate is one way that BLBC tumors are thought to acquire the hallmarks of their 
aggressive nature through the enhanced chance of genetic variation. Both EZH2 
and CDK2 activity have been linked to the aid of BLBC/TNBC tumors acquiring 
genomic instability and consequent increased proneness to mutational genetic 
acquirements suggestive of their activity producing and being an essential 
component of breast cancer with the basal-like phenotype. Specifically aberrant 
or hyperactivation of CDKs (i.e. CDK2) or EZH2 through the PRC2  has been 
shown to favor tumor development via expansion of cancer stem or progenitor 
cells through unscheduled cell division in such upper lineage breast cancer cell 
populations. Therefore inhibition of CDK2 or EZH2 may be a suitable 
intervention and drugable strategy for treating BLBC. Based on acquired 
knowledge that EZH2 T416 phosphorylation can enhance tumor sphere growth 
we developed a tumor sphere drug killing assay using BLBC-derived spheres as 
cell line test subjects. The rationale being that progenitor cells or stem cells from 
the tumor are most resistant with plasticity elements capable of generating or 
regenerating tumor biology heterogenic hierarchy components that are resistant 
to conventional and known BLBC proposed therapies. Therefore, if candidate 
therapy regimens show positive results in the sphere assay it provides a 
through-put design to test and optimize CDK or EZH2 based therapy treatment 
plans. Further validation can be achieved in vivo after initial sphere assay 
screening. Drug developers have sought pharmacological inhibitors for various 
CDKs for decades. Despite attempts to synthesize inhibitors against specific 
CDKs most of the first and second round CDK drugs are pan-CDK inhibitors 
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exist owed to the high homology between CDK members. Some CDK drugs 
have progressed to Phase 2 and Phase 3 of clinical trials therefore CDK 
inhibitors show some promise. Matching the correct CDK inhibitor to the correct 
tumor type is important and also very challenging due to the pan-CDK inhibition 
and CDK-tumor dependency reported108,110. Alternative efforts have focused on 
generating antagonist peptides representative of specific CDK substrates. Short 
peptides representing native amino acid sequences representative of CDK2 
phospho-sites competing with CDK from binding to and phosphorylating the 
endogenous protein. A 39 amino acid peptide named SPA310 representative of 
the retinoblastoma-like protein 2 (RBL2), a known CDK2 bona fide 
phosphorylation substrate, was designed utilizing this competitive antagonist 
strategy. Successfully SPA310 was able through its inhibitory effect on RBL2 
phosphorylation by CDK2 inducing apoptosis and suppressing tumor growth111. 
Utilization of the native peptide used to generate our “in-house” custom T416 
phospho-EZH2 antibody may provide a CDK2 substrate competitive peptide 
strategy similar to SPA310-RBL2 case. Synthesizing a linker sequence for 
cellular entry to increase membrane permeability would permit peptide entrance 
into the cell directed toward EZH2 canonical nuclear localization. Our study 
demonstrates EZH2 T416 phosphorylation has potential as a prognostic marker 
in BLBC and demonstrates the ability to promote tumorigenesis therefore by 
inhibiting EZH2 T416 phosphorylation through peptide competition we can 
provide a suitable treatment for BLBC patients exhibiting elevated levels of T416 
phosphorylation. This presents an interesting hypothesis which requires further 
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development. Moreover our study does not rule out redundancy of other CDKs 
phosphorylating T416 on EZH2 therefore a pan-CDK inhibitor that can inhibit 
other CDKs capable of phosphorylating EZH2 in addition to CDK2 may still be a 
better therapeutic sword. Current CDK drugs in clinical trial and applied tumor 
type are listed in Table 5. 
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Table  5. Current clinical status of CDK inhibitors 
Inhibitor Targets Clinical Trial Sponsor 
AG-024322 CDK1,CDK2 
CDK4 
Phase I, advanced cancer Pfizer 
AT-7519 CDK1,CDK2 
CDK4,CDK5 
Phase I/II, advanced or metastatic 
cancer 
Astex 
P276-00 CDK1,CDK4 
CDK9 
Phase I/II, refractory neoplasms Piramal 
P1446A-05 CDK4 Phase I/II, advanced refractory 
neoplasms 
Piramal 
PD0332991 CDK4,CDK6 Phase I, advanced cancer Pfizer 
R547 CDK1,CDK2 
CDK4,CDK7 
Phase I, advanced solid tumors Holfmann- 
LaRoche 
Roscovitine CDK1,CDK2 
CDK7,CDK8 
CDK9 
Phase II, non-small cell lung cancer, 
haematological cancer 
Cyclacel 
SNS032 CDK1,CDK2 
CDK7,CDk9 
Phase I/II B-lymphoid malignancies 
Phase I/II solid tumors 
Sunseis 
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To assess the CDK2-dpendency on sphere growth MDA-MB 231-vector, MDA-
MB 231-EZH2-WT, MDA-MB 23-EZH2-T416A, and MDA-MB 231-EZH2-T416D 
stable lines were cultured in Mammocult media from StemCell. Previously 
different capacity for sphere number was established based on modulation of the 
T416 EZH2 phosphorylation site therefore sphere number was normalized before 
adding chemical inhibitors for either CDK2 or EZH2. One of the most specific 
CDK2 inhibitors, SNS032 was used to treat spheres derived from MDA-MB 231 
stable EZH2 cell lines. Roscovitine was used and showed similar results. Both 
inhibitors were effective at reducing sphere number after drug treatment for 7-10 
days. Sphere number was reduced by %60 after SNS032 treatment compared 
DMSO control treatment. shCDK also reduced sphere number by a comparable 
margin compared to shLuc control. The MDA-MB 231-EZH2-T416D phospho-
mimetic cell line for EZH2 T416 phosphorylation exhibited 3-fold more resistance 
to SNS032 treatment. This sphere killing assay data suggests BLBC-derived 
spheres number can be reduced by depleting cells of active CDK2. As spheres 
represent the most challenging cell population of breast cancer due to their 
intrinsic stem or progenitor cell characteristic this assay can serve a screen for 
the efficacy of other inhibitors in the treatment and reduction of breast tumor 
sphere numbers, such as treatment with other CDK2 inhibitors or EZH2 
inhibitors. 
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5.4. Utilizing EZH2 inhibition to reduce tumor sphere growth in BLBC 
 EZH2 is the histone methyltransferase component of the polycomb 
repressive complex 2 (PRC2), which initiates transcriptional repression via 
histone 3 K27 tri-methylation (H3K27Me3) target gene promoter regions8. EZH2 
expression correlates with advanced tumor stage and increased mortality specific 
to TNBC patients. EZH2 function has been shown to enhance tumor progression, 
metastasis, angiogenesis, and the population of breast tumor initiating cells. 
Therefore inhibiting tumor progression through specific inhibition of EZH2 has 
been a sought after therapeutic strategy for over a decade. The issue with 
developing a specific inhibitor against EZH2 is it’s off target inhibition of other 
methyltransferases. Off target effects are wide-spread in the cell as protein lysine 
and arginine methyltransferases are ubiquitously expressed and serve to govern 
a vast array of cell functions. This off-target effect will reduce the efficacy of a 
therapy meant to treat cancers dependent on EZH2 as the decided directional 
target for the therapy. A cyclopentenyl derivative of 3-deazaadenosine called 3-
deazaneplanocin A (DZNep) was the first line of EZH2 inhibitor following this 
trend, but as mentioned it has the such aforementioned broad scope of off target 
effects against other lysine and arginine methyltransferases. DZNep inhibits S-
adenosyl-homocysteine (SAH) hydrolase, the enzyme needed for the conversion 
of SAH to adenosine and homocysteine via hydrolysis.  This inhibition results in 
the intracellular accumulation of AdoHcy or SAH, which leads to inhibition of the 
S-adenosyl-l-methionine dependent lysine methyltransferase activity82,112. EZH2 
is a member of the protein lysine methyltransferases (PKMTs) protein family that 
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catalyzes methyl group transfer from s-adenosyl-l-methionine (AdoMet or SAM) 
to the epilson amine group of lysine. Figured 11depicts how SAM is converted to 
SAH resulting in lysine or arginine methylation. This process reduces the level of 
required PKMT substrate for lysine methylation and inhibits PKMTs. DZNep has 
been shown to reduce the levels of PRC2 component expression, including 
EZH2 and SUZ12, through what is thought to be transcriptional regulation in 
different types of cancer including breast cancer cells. As a result of the 
downregulation of the PRC2 components there is a concomitant loss of H3 
lysine-27 trimethylation and a re-expression of PRC2 target genes. As a result, 
DZNep has shown capabilities to inhibit tumor development and induce tumor 
cell apoptosis in several cancer types82,112,113. At tumor-responsive doses, 
DZNep has been reported not to harm non-transformed cells82, but this report is 
controversial as it was shown to be effective treating BRCA1-deficient basal-like 
breast cancer cells, but animal showed high levels of toxicity114. 
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Figure 11. Protein methyl transferase (PMTs) enzymatic processing scheme 
of SAM conversion to SAH during substrate methylation.  
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More specific EZH2 inhibitors would provide targeting EZH2 methyltransferase 
activity without reduction of PRC2 components with less cytotoxic effects. Both 
GlaxoSmithKline (GSK)115 and Epizyme116,117 have independently and 
successfully reported the development of such small molecule inhibitors of EZH2. 
These inhibitors have been test piloted by both drug companies in lymphomas 
with EZH2 activating mutations. GlaxoSmithKline named its inhibitor GSK126 or 
GSK343, and has made this available as part of the SGC epigenetics initiative.  
GSK343 inhibits EZH2 with an IC50 of 4nM and is 1000-fold more specific EZH2 
than for other HMTs. It is 60-fold more selective for EZH2 in comparison to 
EZH1115. Epizyme reported results that were similar to GSK343 for its compound 
EPZ-6438. EPZ-6438 was 4500-fold more specific than for the other HMTs 
tested and 35-fold more selective against EZH1116,117. Both drugs notably reduce 
H3 lysine-27 trimethylation, but do not decrease expression of PRC2 
components as seen with the first line of EZH2 inhibitor, DZNep. The chemical 
structure for GSK343 and EPZ-6438 can be seen in Figure 12. Moreover EPZ-
6438 demonstrated good oral bioavailability in animals making it suitable for in 
vivo studies. No such report was available for GSK343 as of yet. Interestingly in 
June 2013 an EPZ-6438 based Phase 1 and Phase 2 clinical trial was initiated by 
Epizyme in patients with advanced solid tumors or with relapsed or refractory B-
cell lymphoma. This is the second histone methyltransferases drug under clinical 
trial through Epizyme. The second drug under clinical development is called 
DOT1L. Epizyme granted Eisai a worldwide license to EPZ-6438 and in 
collaboration with Eisai and Roche to develop companion diagnostic tests. 
  
147 
Figure 12. Chemical structures of specific EZH2 inhibitors in the clinical 
trial pipeline 
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In our study we wished to decipher how EZH2 inhibition using EZH2 specific 
inhibitors can reduce sphere number. Due to the timing of the study we used 
GSK126 because it was available for use through GSK. Further study should 
include using EPZ-6438 but at the beginning of the sphere killing assay EPZ-
6438 was not available. To assess the EZH2-dpendency on sphere growth MDA-
MB 231-vector, MDA-MB 231-EZH2-WT, MDA-MB 231-EZH2-T416A, and MDA-
MB 231-EZH2-T416D stable lines were cultured in Mammocult media from 
StemCell. Previously different capacity for sphere number was established based 
on modulation of the T416 EZH2 phosphorylation site so sphere number was 
normalized before adding chemical inhibitors for EZH2. Both GSK126 and 
DZNep was used to treat spheres derived from MDA-MB 231-vector, MDA-MB 
231-EZH2-WT, MDA-MB 231-EZH2-T416A, and MDA-MB 231-EZH2-T416D. 
DZNep data is not shown. Independently of T416 phosphorylation status the 
EZH2 inhibitor, GSK126 was able to reduce the sphere number by greater than 
%80. GSK126 treatment circumvented any resistance from the T416D cell line 
observed under SNS032 treatment. Taken together this suggests that EZH2 
inhibitor, GSK126 is very effective at killing tumor spheres derived from the BLBC 
MDA-MB 231 candidate cell line. GSK126 should be tested in additional BLBC 
cell-derived sphere models. 
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5.5. Study summary and conclusion 
 In summary, basal like breast cancer has very limited targeted therapies 
available treatment. Other subtypes of breast cancer have available such 
targeted therapies that are based on molecular classification and therefore these 
types of presented tumors can be handled and is the reason why breast cancer 
mortality rates are on the decline. But because breast cancer is the most 
common type of tumor developed in women and %15-20 of breast cancer 
diagnosed is BLBC, which consequently makes these cases “untreatable”, a 
major endeavor for breast cancer researchers to undertake is in order to provide 
mammary oncologist with suitable treatment options is presented. Discovering 
new biomarkers for the prediction of the onset of BLBC tumor development, to 
provide new therapy targets tumor treatment, and to predict therapeutic 
resistance or response are all essential for learning how to treat BLBC patients. 
As mentioned this subtype of breast cancer is referred to as triple-negative 
breast cancer when the BLBC tumor lacks the expression of ERα, PgR and Her2. 
As reported and previously mentioned CDK activity and EZH2 epigenetic function 
is important for BLBC tumor biology. Moreover, phosphorylation of EZH2 by 
cyclin dependent kinases (CDK) has recently has been reported to control EZH2 
epigenetic function consequently controlling cancer cell proliferation, invasion, 
and stem cell differentiation. By means of establishing that EZH2 and Cyclin E, 
the enzymatic activator of CDK2, co-expressed with clinical significance in triple-
negative breast (TNBC) patient compared to normal breast cancer and that 
CDK2 phosphorylates EZH2 endogenously on residue T416 in breast cancer cell 
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lines in a cell cycle-dependent manner with observed clinical significance to 
reduction in TNBC patient survival exclusively in TNBC tissue we are able to 
propose EZH2-T416 phosphorylation (pT416) now as a potential therapeutic 
biomarker. Our study further concludes the functionality of pT416 as an enhancer 
of EZH2 to increase TNBC cell migration/invasion, mammosphere formation, and 
in vivo tumor growth. Mammosphere formation are both mitigated with 
administration of CDK2 clinical trial inhibitor SNS032 or GSK126 EZH2 specific 
inhibitor therefore, from our study we further postulate pT416 to be a therapeutic 
biomarker for aggressive forms of breast cancer and propose CDK2 or EZH2 
inhibitor based therapies to reduce the size of the breast cancer stem or 
progenitor cell populations and tumor size. In conclusion, the components of this 
study describe a rationale to proceed to preclinical animal models with the 
perspective of later clinical studies for designing new therapeutic regimens of 
CDK based and EZH2 based inhibitors for the treatment of TNBC patients. 
5.6. Future directions 
 The work from this study establishes T416 phosphorylation of EZH2 as 
prediction marker of poor survival in TNBC patients with endogenous cell line 
data supporting the role of T416 phosphorylation promoting an increase in breast 
cancer tumorigenesis.  Development of a mammosphere killing test 
demonstrated to be a useful screening assay to establish a CDK2 based or 
EZH2 based inhibitor treatment can reduce mammosphere number in a cell 
culture setting. From this study there are three forward areas to pursue (1) 
development and validation of a preclinical mouse model for CDK2 and EZH2 
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BLBC therapies (2) identification of PRC2 gene targeting elicited by T416 
phosphorylation (3) expansion of our kinase and EZH2 regulation protein 
knowledge during the cell cycle and in TICs. To validate the CDK2 and EZH2 
therapies the drug treatments should be administered in xenograft mice 
harboring BLBC tumors. Monitoring of tumor growth can accomplished through 
labeling the tumor cells with fire-fly luciferase in order to increase the sensitivity 
of the assay. Tumor size in these models should decrease after SNS032 
treatment concordantly with reduction in T416 phosphorylation observed in the 
tumor tissue or H3K27Me3 reduction observed after GSK126 treatment. 
Evaluation of BLBC tumor growth in such a xenograft model provides a more in 
vivo pre-clinical development strategy for the SNS032 or GSK126 drug regimen. 
Moreover to determine if T416 phosphorylation can promote the development of 
BLBC phenotypic tumors therefore in order to study what biology is regulated 
directly by EZH2 phosphorylation in an in vivo context we have generated a 
conventional transgenic mouse of the oncogenic activating form of EZH2 driven 
by MMTV-LTR promoter TgEZH2T416D, respectively. Early determination of 
tumor development demonstrated no tumors in these mice suggesting a second 
hit is necessary. Therefore this mouse strain will be crossed with BRCA1/P53 
deficient mice or viral tumor induced mouse strains to study how T416 
phosphorylation promotes tumor development in vivo. Mechanistically our study 
produced very little data determining the epigenetic profile that is regulated by 
T416 phosphorylation. In order to determine the epigenetic mosaic of tumor 
biology controlled by T416 phosphorylation we should employ the use of next 
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generation Chip-sequencing technologies. Global levels of histone transcriptional 
initiation, elongation, and repression (in this case H3K27Me3) will be determined 
using defined epigenetic histone modification Chip antibodies in cells with EZH2-
WT, A-form, and D-forms stably expressed Changes in gene activation will be 
determined based on these histone modifications present in the target gene 
promoter region. The gene activation or inactivation will be organized into 
functional categorical subset groups. In this way between the three cellular 
contexts mentioned above the functional mosaics regulated by T416 
phosphorylation can be determined and secondary targets for therapy can be 
developed and validated by shRNA knockdown of the identified targets. In 
addition to how EZH2 is modulated in its gene repression ability by T416 
phosphorylation this study demonstrated that EZH2 is regulated during the cell 
cycle and there is potential for identifying other proteins that regulate EZH2 in a 
cell cycle dependent manner that can aid in the treatment of BLBC. BLBC has 
dependency on many CKDs therefore alternate molecules effect EZH2 can be 
used to gain BLBC fundamental insight for later prospecting potential therapies. 
Determining EZH2 interacting proteins that cell cycle dependent can be done 
synchronizing BLBC cells in respective cells stages and performing IP-Mass-
Spec. Perhaps these changes in protein partners reflect a control mechanism 
that can keep the oncogenic activities of EZH2 in check through the cell cycle 
progression.  This study also in trend with current literature depicts that post-
translational modification (PTM) specifically by kinase phosphorylation can 
regulate EZH2 function and PRC2 targeting to respective gene loci. Our study 
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suggests that T416 phosphorylation can promote tumor sphere formation and it 
is known EZH2 overexpression can promote expansion of the breast cancer 
stem cell population. It is possible that PTM by phosphorylation can regulate 
EZH2 which then can modulate EZH2 oncogenic regulation of the breast cancer 
stem or progenitor cell population. Identification of kinase interacting partners for 
EZH2 in the for example the breast cancer stem population will elucidate kinase 
phosphorylation on EZH2 that is essential for regulating cancer stem cell biology 
and by targeting this phosphorylation by using kinase inhibitors we can then 
potentially reduce or eliminate the breast cancer stem cell niche. EZH2 kinase 
antibody microarray and IP-Mass spec has been utilized in our lab to identify 
these novel kinase partners of EZH2 in FACS sorted CD44-high/CD24-low cell 
populations. Comparison to the kinase interacting partners of EZH2 in non-breast 
cancer stem cells should further validate the biological importance of kinase 
partners that phosphorylate EZH2 in the breast cancer stem cell population 
preserving the oncogenic and therapy resistant nature of this upper lineage 
breast cancer cells. It is known that the sphere formation by these progenitor or 
stem cells from the tumors is a primary assay to decipher if cells are indeed 
upper lineage breast cancer cells. Therefore using the sphere killing assay can 
serve as a preliminary test to validate the importance of new identified EZH2 
kinase binding partners capable of phosphorylating EZH2.  
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